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Abstract 
 
Allogeneic hematopoietic stem cell transplantation is a potential cure for many malignant 
diseases. However, the possibility of chronic Graft-Versus-Host Disease (GVHD) is a 
major obstruction to the therapeutic results. Development of novel therapies has been 
hindered by an incomplete knowledge of the mechanism of disease. This is in part due 
to a lack of relevant mouse models. Using a new murine model of chronic GVHD we 
shed light on the mechanism of disease as well as proposed novel therapeutics that 
could be beneficial for the treatment of chronic GVHD. First, we demonstrate that B cells 
derived from the donor bone marrow are necessary for the progression of disease and 
that these B cells had to produce class-switched antibodies. The production of class-
switched antibody is dependent on the germinal center reaction. The need for the 
germinal center is further highlighted by the requirement for the presence of T follicular 
helper cells. These specialized cells promote the germinal center reaction by providing 
survival signaling to B cells through the IL-21 cytokine and ICOS and CD40 
costimulatory molecules. We further provide evidence that T follicular helper cells and 
the germinal center reaction are necessary by demonstrating that therapeutic depletion 
of B cells during active chronic GVHD is unable to prevent the progression of disease. 
Finally, we demonstrate the importance of B cell signaling following antigen stimulation. 
Inhibition of the B-cell signaling molecule Syk directly down-stream of B-cell receptor 
signaling is sufficient to prevent the progression of chronic GVHD. Collectively this work 
identifies important B-cell survival signals that are necessary for the development of 
chronic GVHD. 
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Allogeneic Hematopoietic Stem Cell Transplantation 
 
 Development of blood cells takes place in the bone marrow, where 
hematopoietic stem cells (HSCs) differentiate into the cells that constitute the 
blood such as red blood cells, leukocytes, and platelets. The leukocyte 
population comprises the cells of the innate and adaptive immune system. 
Without these cells, hosts would be susceptible to infections and would not 
survive. These cells are also important for preventing the onset of malignancies.  
 Due to the rapid creation and turnover of the blood and bone marrow 
compartments there is a high risk of genetic mutations that can lead to the 
development of cancer. Leukemia and lymphoma are malignancies of the blood 
and bone marrow. There are over 30,000 new cases of leukemia annually and 
roughly 70% of people will die from the malignancy. For many of these diseases 
the only cure is a HSC transplantation (HSCT), where patients are ablated of 
their malignant bone marrow by chemotherapy and given healthy bone marrow 
from a donor. The donor bone marrow can come from the same host, a sibling, 
or a non-related host. There are many benefits and complications from each 
donor source. With an autologous, same, or sibling donor there is a decreased 
risk of graft-rejection compared to an allogeneic, non-related, donor. However, 
the risk of tumor relapse is decreased with an allogeneic donor compared to the 
autologous or sibling donor1.  
Allogeneic hosts offer an increased clearance of the leukemia or 
lymphoma following HSCT. However the risk of rejecting the recipient by the 
donor’s immune-competent cells can occur. Graft-versus-Host disease (GVHD) 
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is a major complication following HSCT. GVHD can occur in 19-66% of sibling 
and 90% of unrelated allogeneic donors and leads to a mortality rate of about 
15% of total HSCT recipients2. Due to the high tumor clearance of allogeneic 
HSCT and the relatively low existence of sibling donors – about one in four 
recipients – the need for better understanding of GVHD as well as better 
therapeutics is necessary. 
 
Graft-versus-Host Disease 
Graft-versus-host disease was fist observed as a secondary disease 
following irradiation and transplantation of hematopoietic cells3. Later Billingham 
R.E. defined the three criteria necessary for diagnosis of GVHD4. First, the graft 
must contain immunologically competent cells. It was demonstrated that addition 
of mature hematopoietic cells from the spleen or lymph nodes increased the 
severity of disease.5 Further research has demonstrated that thymus-derived 
lymphocytes (T cells) are the key cell required for development of GVHD6. 
Depletion of T cells from the donor graft is able to prevent the development of 
GVHD, but the depletion also removes many beneficial effects as well, such as 
tumor clearance. Second, the recipient must be immune compromised so that 
they are unable to reject the graft. This occurs with the high levels of 
chemotherapy necessary for eliminating the malignancy. Finally, the recipient 
and donor must have antigen disparity. Major and minor histocompatibility 
antigens (MHC and MiHA respectively) generate immune responses to the host7. 
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It is estimated that 1 in 100 T cells are able to recognize these histocompatibility 
antigens8, in striking contrast to the 1 in 100,000 for other antigens9. 
 GVHD can be divided into two distinct diseases: acute GVHD and chronic 
GVHD.  Pathogenesis of acute GVHD beings with the initiation phase: 
cytoablative conditioning releases proinflammatory cytokines and damages 
epithelial tissues, most notably in the gastrointestinal tract. The release of the 
pro-inflammatory cytokines TNF-a and IL-1 increases with increased doses of 
irradiation10. These cytokines act to increase the activation state of host antigen 
presenting cells11. Damage to the epithelial lining also allows for the release of 
bacterial endotoxin, further amplifying the activation of host immune cells12. 
Furthermore, damage to thymic epithelial cells allows for decreased thymic 
output and an increase in potentially self-reactive T cells13, which can lead to 
increased disease during chronic GVHD. During the activation phase, donor 
mature T cells present in the graft are activated in the pro-inflammatory 
environment created by conditioning. It remains controversial how donor T cells 
recognize antigen presented by host (MHC). T cells can recognize host antigen 
by either direct presentation or indirect presentation or some combination of 
both14. For direct recognition donor T cells recognize either the peptide bound to 
allogeneic MHC or the allogeneic MHC molecule themselves. In contrast, indirect 
recognition involves the T cell binding to degraded recipient MHC presented by 
graft MHC. Finally, activated T cells migrate to target tissues to cause significant 
host tissue destruction15. Acute GVHD is defined by necrosis of target tissues. 
Activation of CD8 cytotoxic T lymphocytes has been shown to be necessary for 
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the progression of disease. Each phase works to amplify the disease causing 
multi-organ system damage.  
 Whereas research in acute GVHD has greatly increased the survival rate 
for transplanted patients, the prevalence of chronic GVHD has increased. This is 
partially due a lack of definition for the disease and the dearth of relevant 
research tools to study disease16. Recently an NIH consensus consortium 
redefined the diagnosis and criteria for disease17, establishing key pathological 
syndromes necessary for diagnosis as chronic GVHD. Previously, any 
complication following 100 days post transplantation was considered chronic 
GVHD. However, there is precedent of late-term acute GVHD that can manifest 
past the 100-day criteria. Therefore incorrect diagnosis and understanding of 
disease was unable to be defined by timing of disease. Finally, the presence of 
accurate research models has remained poor. Murine models of acute GVHD 
can mimic the human disease; however, models for chronic GVHD have not 
replicated the spectrum of the human disease. Many chronic GVHD models 
either do not have the complete cytoablative conditioning regiment or do not use 
cells from relevant donors to cause disease. Furthermore, manifestation of 
disease has been limited to only a couple target organs, such as skin, kidneys, 
and liver instead of a systemic multi-organ disease. Development and 
characterization of a more accurate model is necessary for the understanding 
and ultimately the development of new therapies for chronic GVHD. 
 
Chronic GVHD 
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While chronic GVHD can have different disease manifestations in the 
lung, liver, and skin the pathology has the overlapping key characteristics of 
increased fibrosis (Figure 1). In several instances there has been evidence to 
suggest that B cells play a major role in disease. B cells are antibody-producing 
cells that develop in the bone marrow. After recognition of the cognate antigen 
they interact with specialized T cells to produce high-affinity antibodies in the 
germinal center (GC). Acute GVHD tends to be a B cell eliminating disease, 
however, B cells appear to be activated during chronic GVHD. Early studies 
demonstrated an increase in antibody production to known MiHA. It was 
demonstrated that male recipients receiving female grafts developed antibodies 
toward the male MiHA in the context of chronic GVHD18.  This demonstrated that 
during chronic GVHD antibody to a known MiHA was produced. In addition, the 
level of B-cell activating factor (BAFF) is increased in patients with chronic 
GVHD19, 20. The increase of BAFF to B cell ratio is thought to increase the 
response rate and survival of pathogenic B cells.  
Even though the role of B cells during chronic GVHD is not completely 
understood there is growing evidence that deposition of antibodies in target 
tissues causes disease. Antibody deposition can lead to activation of 
complement and antibody-dependent cellular cytotoxicity. This process involves 
the activation of macrophages or natural killer cells in target tissues by 
recognizing antibody bound to the cognate antigen. The activation of 
macrophages can cause release of pro-fibrotic cytokines that leads to tissue 
remodeling. The increase in antibody deposition in target tissues is correlated 
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with the increase in fibrosis; however, the processes that lead to increased 
fibrosis are not well understood. In some patients there are increases in pro-
fibrotic cytokines such as TGFβ21. There is growing evidence that TGFβ is 
produced by donor macrophages activated by deposited antibody (JCI in press). 
However there are other mechanisms that have been seen in clinic. The 
activation of receptors, such as Platelet Derived Growth Factor Receptor 
(PDGFR), by activating antibodies has also been described22, 23. In this situation, 
antibodies might not be causing the tissue destruction as previously believed; 
instead receptor-activating antibodies might cause the increase in 
fibroproliferation.  
Initiation of disease is dependent on T cells. Presence of mature T cells in 
the graft is necessary for disease in models of chronic GVHD24. B cells interact 
with T cells in the follicle of secondary lymphoid organs to form GC reactions. 
Here T cells provide survival signals to B cells during DNA mutation  to the 
antibody locus in peripheral tissues following antigen stimulation in a process 
known as somatic hyper-mutation. After antigen stimulation, B cells upregulate 
activation induced cytosine deaminase (AID), causing point mutations to the Ig 
locus, these mutations are repaired by non-homologous end joing repair 
mechanism creating mutations in the region. DNA that affects the antigen-
recognizing portion of the antibody it is selected by T cells by receiving cell pro-
survival stimulation or is neglected and undergoes apoptosis25. Specialized T 
follicular helper cells (Tfh) provide cytokine support and selection for B cells 
undergoing somatic hyper-mutation. The cytokine IL21 has been demonstrated 
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to increase the B cell survival and maturation to memory and plasma cells even 
though the GC reaction is not dependent on the expression of IL2126. Signaling 
through the IL21 receptor increases the expression of proteins necessary for 
somatic hyper-mutation and survival factors in B cells. Tfh also provide contact 
dependent signals to B cells through ICOS and CD40 signaling. B cells that are 
able to produce higher affinity antibodies create more stable contacts receive 
increased support from the Tfh.  
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Figure 1: Proposed mechanism of chronic GVHD. Pre-transplant 
conditioning and alloreactive donor T cells leads to a compromised selection in 
the thymus and bone marrow allowing for allo/auto reactive T cells and B cells, 
respectively, to be generated. B cells and T follicular helper cells enter the 
secondary lymphoid organs and form germinal centers reactions to allo/auto 
reactive antigens. B cells differentiate into the antibody-producing cell, Plasma 
cells, which produce highly specific antibodies that bind target tissues and 
activate macrophages, releasing pro-fibrotic cytokines. This leads to a positive-
feedback loop increasing fibrosis and tissue damage and allowing more 
allo/auto reactive B cells to undergo the germinal center reaction. 
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Chapter II: Donor B-cell alloantibody deposition and germinal center 
formation are required for the development of murine chronic GVHD and 
bronchiolitis obliterans 
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Chronic GVHD poses a significant risk for HSCT patients. Preclinical 
development of new therapeutic modalities has been hindered by models with 
pathologic findings that may not simulate the development of human chronic 
GVHD. Previously, we have demonstrated that chronic GVHD induced by 
allogeneic HSCT after a conditioning regimen of cyclophosphamide and total-
body radiation results in pulmonary dysfunction and airway obliteration, which 
leads to bronchiolitis obliterans (BO), which is pathognomonic for chronic GVHD 
of the lung. We now report chronic GVHD manifestations in a wide spectrum of 
target organs, including those with mucosal surfaces. Fibrosis was demonstrated 
in the lung and liver and was associated with CD4+ T cells and B220+ B-cell 
infiltration and alloantibody deposition. Donor bone marrow obtained from mice 
incapable of secreting IgG alloantibody resulted in less BO and chronic GVHD. 
Robust germinal center reactions were present at the time of chronic GVHD 
disease initiation. Blockade of germinal center formation with a lymphotoxin-
receptor–immunoglobulin fusion protein suppressed chronic GVHD and BO. We 
conclude that chronic GVHD is caused in part by alloantibody secretion, which is 
associated with fibrosis and chronic GVHD manifestations including BO, and that 
treatment with a lymphotoxin-β receptor–immunoglobulin fusion protein could be 
beneficial for chronic GVHD prevention and therapy. 
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Introduction 
Chronic GVHD is a significant complication of allogeneic HSCT27. 
Progress in developing interventional strategies to counter chronic GVHD has 
been hampered by variable onset and pathologic manifestations of chronic 
GVHD, now better defined by the National Institutes of Health consensus 
conference,17 and a dearth of robust preclinical venues that closely mimic 
conditions in which chronic GVHD is generated and manifested16. 
Although the exact causes of chronic GVHD are unknown, higher antibody 
levels have been associated with autoimmunity and implicated in chronic 
GVHD28, 29. Studies of newly diagnosed patients with extensive chronic GVHD 
showed that they had elevated soluble B-cell activating factor (BAFF) levels and 
anti-ds-DNA antibodies30, 31. Increased soluble BAFF in chronic GVHD was 
associated with higher circulating levels of pre–germinal center (GC) B cells and 
post-GC plasmablasts19. B cells from chronic GVHD patients are hyper-
responsive to TLR-9 signaling and have up-regulated CD86 levels32, which 
suggests an important participatory role for B cells in establishing chronic GVHD 
and emphasizes the need for further investigation into the immunologic role of B 
cells in chronic GVHD pathogenesis. 
Existing murine chronic GVHD models simulate one or more of the 
pathologic manifestations, such as increased serum antibodies (typically anti-
DNA antibodies), scleroderma, and fibrosis of skin and liver, and the less 
common immune complex deposition in kidneys and glomerulonephritis33-35. The 
type of multi-organ involvement and alloantibodies seen in chronic GVHD 
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patients often has not been well represented in these preclinical models. 
Moreover, some models do not involve conditioning regimens, whereas others 
rely on radiation alone. Previously, our laboratory has studied pulmonary 
dysfunction and chronic GVHD target-organ pathology in animals conditioned 
with high-dose cyclophosphamide (Cy) and lethal total-body irradiation (TBI) 
rescued with allogeneic BM and splenocytes36. The functional, physiologic, and 
pathologic assays demonstrated that Cy and TBI–conditioned recipients of low 
numbers of allogeneic T cells developed bronchiolitis obliterans (BO)37, 38. BO, 
characterized by airway blockade, peribronchiolar fibroproliferation, and 
obliteration of bronchioles, is a late-stage complication of GVHD, prevalent in 
2%-3% of HSCT patients and up to 6% of patients who develop GVHD39. 
Patients diagnosed with BO have a 5-year survival rate of only 10% versus 40% 
in patients without BO37. According to the National Institutes of Health consensus 
criteria17, BO is the only single pathognomonic manifestation of chronic GVHD of 
the lung; therefore, this is a bona fide chronic GVHD murine model. 
In the present study, we identified the presence of CD4+ Th cells and 
B220+ B cells in the airways of mice that had BO, tissue-specific antibodies from 
sera, and alloantibody deposition in the lung and liver of chronic GVHD 
recipients. Through studies using wild-type (WT), knockout, and transgenic donor 
cells, we conclusively demonstrate that donor alloantibody secretion is essential 
for BO generation, providing a preclinical model in which to test interventional 
and prophylactic approaches for chronic GVHD. 
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The mainstay of treatment of chronic GVHD and BO is anti-inflammatory 
therapy. Corticosteroids are contained in many of the current regimens but are 
still associated with a high rate of progressive airway obliteration and subsequent 
mortality40. Treatment of steroid-refractory chronic GVHD patients with rituximab, 
a B cell–depleting anti-CD20 mAb, has shown a beneficial role in resolution of 
autoimmune disorders such as systemic lupus erythematosus and rheumatoid 
arthritis41, as well as chronic GVHD18, 42-44. Aggregate analysis of 6 trials of 
steroid-refractory chronic GVHD showed overall response rates of 29%-36% for 
oral, hepatic, gastrointestinal, and lung chronic GVHD and 60% for cutaneous 
chronic GVHD45. 
Additional prevention and treatment strategies clearly are needed. We 
focused on GC formation, critical for efficient class switching and antibody 
secretion by mature B cells and plasma cells. Lymphotoxin-β (LTβ)–LTβ receptor 
(LTβR) interactions are essential for GC formation and maintenance, ensuring 
proper anchoring of GC B cells within the network of follicular dendritic cells 
(DCs) and correct GC formation. Inhibiting the GC reaction and subsequent 
antibody secretion has proved to be efficacious in some systemic lupus and other 
autoimmune models in which B cells and antibody secretion have been 
implicated in pathology41. LTβR-Ig is a novel fusion protein that binds circulating 
lymphotoxin and inhibits LT-LTβR signaling46. We show that LTβR-Ig treatment of 
transplanted animals susceptible to the establishment of chronic GVHD and BO 
resulted in improved lung function along with lower tissue-specific antibody levels 
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in the sera and fibrosis of the lung and liver. LTβR-Ig represents a potential new 
therapy for chronic GVHD prevention and treatment. 
 
Results 
Multiorgan pathology with fibrosis in Cy/TBI recipients experiencing 
chronic GVHD 
B10.BR mice were conditioned with Cy/TBI and received either BM alone 
(BMT control group) or BM with low-dose splenocytes to induce a chronic 
alloresponse not associated with early post-BMT mortality. Weight curves (Figure 
1 A) and 2-month survival rates were ≥ 90% and were comparable between 
groups (Figure 1 B). On day 60, PFTs in the chronic GVHD group (Figure 1 C) 
demonstrated lung dysfunction consistent with BO36. The PFTs showed an 
increase in airway resistance, which correlated with lung constriction, increased 
elastance, and decreased compliance, which signifies increased stiffness or 
rigidity of the lungs. These data simulate BO manifestations in chronic GVHD 
patients39. A decrease in pulmonary function and increased pathology was 
noticed as early as 28 days after transplantation (Figure 1 D; supplemental 
Figure 2). Therefore, this system is a bona fide model of chronic GVHD based on 
extrapolation of the National Institutes of Health's consensus criteria for chronic 
GVHD diagnosis in patients17. The chronic GVHD group displayed multiorgan 
pathophysiology consistent with chronic GVHD (Figure 2 A-B). Lung histology 
showed peribronchiolar infiltration and cuffling denoting the onset of obliteration 
of the bronchioles (Figure 2 A). Many animals displayed distal pathology in the 
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lungs, including protein exudation, macrophage infiltration, and the start of tissue 
remodeling (supplemental Figure 1). Lung pathology scores were significantly 
higher in the chronic GVHD group than in BMT controls (Figure 2 B). In the liver, 
perivascular infiltration was observed surrounding the bile duct and extending 
into the parenchyma (Figure 2 A), which resulted in a significant increase in the 
pathology score in the chronic GVHD versus the BMT control animals (Figure 2 
B). Mice with higher pathology scores also had necrotic foci of cells in the 
parenchyma proper. Because patients with chronic GVHD may also have oral 
mucosal involvement, histopathology of the tongue and salivary glands was 
examined. Areas of infiltration, inflammation, and abscess formation were 
observed on the tongue near the taste receptors (Figure 2 A). The pathology 
score was significantly higher, albeit modest in magnitude, in the chronic GVHD 
group than in the BMT-only controls (Figure 2 B). Salivary glands displayed 
perivascular infiltration; however, this infiltration was also seen in the BMT 
controls, which suggests changes resulting from the conditioning (Figure 2A). 
The thymus, known to be involved in human chronic GVHD13, displayed 
necrotic foci and destruction of stromal matrix, which resulted in a significantly 
higher chronic GVHD pathology score. The spleen had abnormal architecture 
similar to the thymus, albeit only modest differences were seen in the pathology 
score. The colon displayed moderate pathology in the chronic GVHD cohorts, 
although it was not as extensive or invasive as in acute GVHD models. The ileum 
displayed the mild pathology seen in both the chronic GVHD and the BMT group, 
which suggests the role of pretransplantation conditioning. 
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Chronic GVHD has been characterized as a fibroproliferative disease, and 
therefore, collagen levels were quantified by trichrome staining. The lung and 
liver (Figure 2 C-D) both displayed a significant increase in collagen deposition 
around bronchioles and blood vessels. The organization of the collagen 
surrounding the bronchioles and blood vessels is highlighted and demonstrates 
that the increase in collagen was localized to specific structures and not 
uniformly distributed throughout the lungs and liver (Figure 2C). Fibrosis patterns 
in tongue and salivary glands were somewhat more variable between individual 
mice within a group, and trichrome staining was not increased significantly 
compared with the BMT controls (data not shown). 
Overall, Cy/TBI conditioning followed by the transfer of a low-splenocyte 
infusion reproduced the pathology of chronic GVHD. It was distinguished from 
acute GVHD by the absence of significant weight loss early and overall mild 
losses later after transplantation, BO, involvement of the oral mucosa, and 
fibrosis in chronic GVHD target organs. Although pathology and fibrosis in the 
lung have been observed previously36, documented reports of pathology in the 
other organs have not been evaluated. 
 
CD4+ T-cell and B-cell infiltration and alloantibody deposition in chronic 
GVHD target organs 
We sought to determine the potential etiopathogenic mechanisms 
associated with chronic GVHD. We focused on the lung and liver as the two most 
severely affected chronic GVHD organs denoted by obstructive PFTs and the 
presence of fibrosis. CD4+ T-cell infiltration was observed in peribronchiolar 
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areas in the chronic GVHD group but not in BMT-only controls (Figure 3A). The 
liver displayed substantial infiltration in the perivascular areas (Figure 3A) and, 
for some recipients, into the parenchyma (not shown). Because of the degree of 
lung inflation influencing the distribution of cells, percentages of lymphocytes 
were quantified in the lung versus the total number. The number of CD4+ T cells 
in the lung (Figure 3B) and the liver (Figure 3C) was significantly higher in the 
chronic GVHD group than in the BMT-only control group, consistent with other 
models in which CD4+ T cells could be found in chronic GVHD organs33. There 
was only minimal infiltration of CD8+ T cells in both groups (data not shown). 
B220+ B-cell infiltration in the lung and liver (Figure 3D) was seen in a pattern 
similar to that of CD4+ T cells. A significant increase in total B220+ B cells in the 
lung and liver was seen in the chronic GVHD group compared with the BMT 
controls (Figures 3E and 3 F, respectively). Salivary glands and the tongue had 
only minimal B220+ B-cell infiltration (data not shown). Taken together, the 
pathology in the lung and liver was associated with CD4+ T-cell and B-cell 
infiltration. We hypothesized that B cell–secreted antibodies might play a role in 
chronic GVHD pathology and determined whether antibody deposition could be 
observed in chronic GVHD organs on day 60 after transplantation. The lung and 
liver had deposits of mouse Ig within surrounding areas of infiltration and 
pathologic effects (Figure 4A). There were peribronchiolar deposits and 
perivascular deposits in both organs. Quantification of Ig deposition in the lung 
and liver (Figure 4B) revealed higher levels in the chronic GVHD group than in 
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the BMT controls. The predominant Ig type was IgG2c in the lung and liver 
(supplemental Figure 3 and data not shown).  
To determine whether circulating anti-host tissue-reactive antibodies were 
present, sera from transplanted animals were incubated with tissues from a naive 
B10.BR mouse and then probed with fluorochrome-labeled anti-mouse Ig (Figure 
4 C). Fluorescence was evident in the perivascular areas in lung and liver and in 
the peribronchiolar area in lung. These results indicate that circulating host 
tissue-reactive antibodies may contribute to chronic GVHD pathology. 
 
chronic GVHD pathogenesis requires the production and secretion of anti-
host reactive antibodies 
To further test our hypothesis that B cells and secreted alloantibodies play 
a causative role in establishment of chronic GVHD, we used donor µMT mice 
that do not have membrane-bound IgM and are deficient in mature B cells 
(Figure 5). To limit the contribution of donor B cells and avoid any issues related 
to defective regulatory T-cell dysfunction reported in µMT mice, Cy/TBI-
conditioned recipients received WT or µMT BM with or without supplemental WT 
T cells (0.33 × 106). Recipients of WT BM plus supplemental WT T cells versus 
low-dose splenocytes had comparable survival and weight and had significant 
increases in resistance and elastance, with a lowering of compliance that was 
characteristic of BO. When recipients of B cell–deficient BM and WT T cells were 
compared with mice with chronic GVHD that received WT BM with WT T cells, 
PFTs demonstrated lower resistance, elastance, and higher compliance (Figure 
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5A). Control recipients of WT compared with µMT BM had comparable 
parameters. Recipients of B cell–deficient BM with WT T cells had resistance and 
elastance comparable to that of recipients of B cell–deficient BM without 
supplemental T cells. Thus, donor allogeneic T cells and BM-derived mature B 
cells are required for BO generation. In contrast to recipients of WT BM plus T 
cells versus BM alone, there were no significant differences in the histopathology 
scores of lung and liver between mice given µMT BM plus T cells and those 
given WT BM (supplemental Figure 4). Of note, although lymphocyte infiltration 
and inflammation were observed in recipients of µMT BM and T cells, there was 
no destruction of the bronchioles or bile ducts, and the degree of fibrosis mirrored 
the extent of pathologic injury (Figure 5B). The somewhat higher amounts of 
fibrosis in recipients of µMT BM with or without WT T cells may be due to the 
known Treg defect in µMT mice47, which then could have failed to control the 
inflammatory response in the lung and liver in chronic GVHD mice, offsetting in 
part the effect of B-cell deficiency. Moreover, Ig was not deposited in the lung or 
liver of mice that received µMT BM and T cells (Figure 5C), findings that 
correlated with results of PFTs. 
We cannot exclude the possibility that antibody deposition is a bystander 
in the disease process and that the critical pathogenic mechanism is the APC 
function rather than Ig capacity of activated B cells. To distinguish between these 
two fundamental mechanisms, we used (m+s)IgMxJhD BALB/c donors. These 
mice are capable of generating membrane-bound IgM and secreting IgM, but 
they produce and secrete ≥ 100-fold less antigen-specific IgG than similarly 
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immunized WT controls48. They also do not appear to have a regulatory T-cell 
defect like the µMT mice (supplemental Figure 5). Recipients were given WT BM 
or transgenic BM alone or with WT splenocytes. Day 60 PFTs in conditioned 
B10.BR recipients of (m+s)IgMxJhD BM and WT splenocytes had significantly 
lower lung resistance and elastance and higher compliance than recipients of WT 
BM with splenocytes (Figure 6 A). These data indicate that the lack of IgG 
alloantibody secretion by donor BM-derived B cells precluded the pulmonary 
dysfunction associated with BO. This was confirmed by staining tissues for total 
Ig in the lung and liver (Figure 6 D). Mice given (m+s)IgMxJhD BM only and mice 
given (m+s)IgMxJhD BM with splenocytes both had decreased deposition of Ig 
surrounding bronchioles and bile ducts compared with mice transplanted with WT 
BM and splenocytes. Collagen deposition was significantly reduced in mice that 
received (m+s)IgMxJhD BM with splenocytes compared with the WT BM plus 
splenocytes (Figure 6 B). However, infiltrating CD4+ cells were still observed in 
the lung and liver of both mice given WT BM and splenocytes and those given 
(m+s)IgMxJhD BM and splenocytes (Figure 6 C). These data suggest that 
inflammation is not regulated by Ig deposition per se, and therefore, other 
mechanisms (chemokines) are not affected by Ig deposition. The pathogenicity of 
Ig deposition in adversely affecting PFTs may not be the result of changes in 
inflammation but rather in situ injury from complement binding to deposited 
alloantibody or the Ig-facilitated activation of inflammatory or resident cells in situ. 
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Blockade of GC formation is sufficient to prevent BO and hence chronic 
GVHD generation 
Because BM-derived B-cell production and secretion of anti-host reactive 
antibody appear to be critical for chronic GVHD generation, we sought to prevent 
antibody production by interrupting GC formation. GCs are sites where mature B 
cells rapidly proliferate, differentiate, and undergo somatic hypermutation that 
results in the production of class-switched antibody. LTβ, produced by T and B 
cells, and LTβR signaling are required for proper establishment of the follicular 
DC network and the organizational network of functional GCs in lymphoid 
tissues. Given the role of LTβR signaling and our finding that the dominant Ig 
isotype deposited in chronic GVHD target organs was IgG2c, we sought to 
determine whether disruption of LT-LTβR signaling by infusion of a known 
blocking reagent, mouse LTβR-Ig fusion protein, would reduce chronic GVHD 
pathology. Recipients were treated with LTβR-Ig or control fusion protein from 
days 28-52 after transplantation (Figure 7). Treatment began on day 28 because 
of decreases in PFTs (Figure 1 D) and increased GC size and frequency 
(supplemental Figure 8), which indicated early initiation of chronic GVHD. To 
determine the effect of LTβR-Ig on GC formation in chronic GVHD versus BM 
recipients, spleens were analyzed by immunofluorescence (Figure 7 A); peanut 
agglutinin and IgM staining detects GC B cells, whereas VCAM-1 stains follicular 
DCs. Untreated and control mAb-treated mice with chronic GVHD pathology 
displayed prominent GC structures with a well-organized follicular DC network, 
which signifies a robust GC reaction. Mice treated with LTβR-Ig showed 
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disrupted GC structures with an ill-formed follicular DC network. A decrease in 
size and frequency of GC was seen in LTβR-Ig–treated mice (Figure 7 B-C).  
Consistent with the finding that disruption of GC formation would diminish 
BO and chronic GVHD generation, day 60 PFTs in the chronic GVHD cohorts 
indicated that LTβR-Ig–treated but not control protein-treated recipients displayed 
lower resistance and elastance and higher compliance (Figure 7 D). Both liver 
and pulmonary fibrosis was reduced by LTβR-Ig (Figure 7 E). Thus, LTβR-Ig 
treatment given after transplantation ameliorated the development of BO and 
chronic GVHD. The pathologic scores showed that mean lung scores of mice 
given BM plus splenocytes plus MOPC21 were ∼5-fold higher than those that 
received BM plus splenocytes plus LTβR-Ig (supplemental Figure 7), although 
these differences did not reach statistical significance. For the liver, recipients 
given BM with splenocytes treated with MOPC21 had a reduction in mean scores 
compared with those given BM plus splenocytes and no Ig control, thereby 
making it difficult to assess the extent to which LTβR-Ig was superior to 
MOPC21. However, we can state that recipients of BM plus splenocytes had 
higher scores than those of mice BM with splenocytes and treated with LTβR-Ig, 
indicating that the LTβR-Ig did indeed reduce the severity of pathological injury. 
These data are supportive of our findings that LTβR-Ig reduces chronic GVHD as 
measured by PFTs, fibrosis, Ig deposition, and GC formation, all of which 
showed a marked reduction in BO and chronic GVHD manifestations. 
To test our hypothesis that LTβR-Ig treatment works by inhibiting antibody 
secretion by class-switched B cells, we assayed for the presence of host tissue–
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reactive antibodies in the sera of transplanted animals using a serum-binding 
assay. Compared with control mAb–treated recipients, sera from mice that were 
treated with LTβR-Ig had reduced fluorescence in the peribronchiolar area of the 
lung and perivascular area of the liver (Figure 7 F), which indicates that LTβR-Ig 
but not control protein leads to a decrease in the production of anti-host reactive 
antibody, consistent with the improvement in PFTs. 
These results suggest that B cells, via their antibody secretory capability, 
contribute to pulmonary dysfunction and liver pathology in animals that have 
chronic GVHD after transplantation, and interventional strategies that inhibit 
pathways involved in B-cell function and antibody secretion may be useful in the 
prevention or treatment of chronic GVHD. 
Discussion 
We report that Cy/TBI-conditioned allogeneic recipients given low 
splenocyte or T-cell doses developed multiorgan system pathology with fibrosis 
and BO pathognomonic of chronic GVHD of the lung. chronic GVHD 
development was associated with IgG2c deposition in the lung and liver and 
IgG2b in the liver, which was abrogated if the donor BM was deficient in mature 
B cells or incapable of producing anti-host reactive IgG. Robust GC formation 
was seen in mice with chronic GVHD. By disrupting GC formation with LTβR-Ig, 
BO was reduced. Together, these data indicate that GC formation and IgG 
secretion by donor BM-derived mature B cells are necessary for chronic GVHD 
pathology. 
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The use of Cy, which exacerbates TBI-induced glutathione redox 
reactions in the lung49, along with sublethal doses of donor T cells (to avoid acute 
GVHD) favored the generation of chronic GVHD. The histologic changes in this 
model were similar to the findings in human chronic GVHD28. The lungs showed 
peribronchiolar and perivascular cuffing and infiltration of the airway epithelium. 
The pathology appeared predominantly bronchiolar, with some alveolar 
involvement. Completely occluded bronchioles are observed in 20% of the 
animals in this model36. The pattern of inflammation along with increased 
collagen deposition surrounding nonobliterated bronchioles was similar to the 
pathology that defines occluded bronchioles in humans50. The liver had 
inflammation and lymphocytic infiltration, along with collagen deposition in the 
vascular epithelium and around the bile ducts and apoptotic foci in the 
parenchyma. Salivary gland pathology is an important clinical manifestation of 
chronic GVHD; patients suffer from xerostomia, histopathologic analysis shows 
mononuclear infiltration and fibrosis51, 52, and salivary gland injury is a known 
finding in a minor mismatch mouse model of chronic GVHD53. The parotid and 
submandibular salivary glands displayed lymphocytic infiltrates in both the BM 
and chronic GVHD groups, likely because of transplantation conditioning. In the 
tongue, there was a quantifiable difference in the histology; however, the extent 
of inflammation and infiltration was mild to moderate and isolated to small 
regions of the epithelium. Similar profiles of fibrosis were seen in the tongue and 
salivary glands for both control and chronic GVHD groups, which suggests that 
the oral mucosa did not manifest chronic GVHD or that the kinetics were delayed 
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compared with the liver and lung. The absence of any inflammatory or fibrotic 
changes in the skin differs from some other models in which the predominant 
feature is scleroderma (reviewed in Sarantopoulos et al19). This systemic 
histologic profile reinforces the observation that in mice, as in humans, the 
pathologic manifestations of chronic GVHD are heterogeneous. 
The role of CD4+ T cells in both acute GVHD and chronic GVHD has been well 
chronicled. We also observed the presence of CD4+ T cells in the zones of 
inflammation in both lung and liver of affected animals. A significantly higher 
number of B220+ B cells were found clustered with the CD4+ T cells, which sets 
up a situation in which CD4+ T-cell help for B-cell alloantibody production might 
occur in situ in chronic GVHD target organs. Although donor CD8+ T-cell 
involvement has been reported to play a causative role in airway obliteration after 
BMT50, we did not observe a higher incidence of CD8+ T cells in the inflamed and 
affected regions of the lungs or livers (data not shown). We detected antibody 
deposition in the target areas of lung and liver, which confirms the involvement of 
B cells. Examining sera from these animals, we detected the presence of lung 
and liver tissue–specific antibodies. Further characterization is required to 
identify whether these antibodies are donor-versus-host alloreactive or 
autoreactive because of a breakdown in the tolerance processes after BMT. 
Thus, it appears that the tissue modifications and fibrosis stem from a 
coordinated CD4+ T-cell and B-cell response. 
Alleviation of physiologic and histologic symptoms in animals that received 
B cell–deficient BM compared with WT BM confirms the requirement of B cells 
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for lung dysfunction and inflammation and fibrosis in the lung and liver. These 
animals displayed a less restrictive pulmonary physiology and a lower incidence 
of occluded and fibrotic airways, which signifies healthier lungs. The liver 
displayed less intensive inflammation and fibrosis, consistent with a study that 
reported attenuated liver fibrosis after toxin injury in B cell–deficient mice54. The 
use of (m+s)IgMxJhD mice that can only secrete IgM and not IgG248 as donors 
excluded the capacity of donor B cells to facilitate chronic GVHD manifestations 
because of enhanced pathogenic antibody production as a product of class 
switching and affinity maturation. B cells and follicular DCs have intact APC 
function, although the B-cell receptor repertoire is restricted because of the use 
of a fixed IgM-Vh region55. On day 60 after transplantation, the lung physiology 
showed a significantly healthy phenotype compared with the chronic GVHD 
group. The lack of secreted antibody other than IgM alleviated the functional 
consequences of chronic GVHD in the lung. These data indicate that either IgG 
secretion is necessary for pathogenicity or a full B-cell receptor repertoire is 
required to promote disease. The repertoire in turn could control the quality and 
specificity of the alloreactive antibodies secreted, as well as any required APC 
function of specific B cells for pathogenic CD4+ T cells. Further work will be 
required to dissect these two related possibilities. 
Given a role for IgG antibodies, we propose that alloantibody binding to 
chronic GVHD organs could enable tissue destruction and modifications via 
donor cell–mediated antibody-dependent cellular cytotoxicity or antibody-
dependent phagocytosis. Alternatively, the pathology could be defined by the 
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specific function of these secreted antibodies. For example, elevated titers of 
anti-PDGFR antibody have been detected in sera of patients with extensive 
chronic GVHD22. This antibody has been implicated in a signal transduction 
pathway that ultimately leads to the induction of type 1 collagen production and 
fibrosis29. Pathogenic antibody production, therefore, is likely to be an important 
inducer of chronic GVHD, and targeting this specific function of the B cells is an 
attractive strategy to prevent or treat early manifestations of chronic GVHD. 
Treatment of chronic GVHD with the anti-CD20, B cell–depleting antibody 
rituximab ameliorates some manifestations of chronic GVHD, but it rarely results 
in complete remission of chronic GVHD29. In studies using mice and monkeys, it 
has been shown that rituximab treatment is more successful in removal of B cells 
from the blood than from spleen and lymph nodes56, 57. GC B cells display lower 
susceptibility to rituximab-mediated clearance, probably because they reside in a 
nonoptimal environment for antibody-based depletion41. Our observation that GC 
B cells are critical to the development of chronic GVHD suggests that agents that 
are more effective at disrupting the GC might be more useful clinically. We are 
unaware of the use of rituximab in a systemic fashion to determine the effects on 
BO in chronic GVHD patients. Such studies would require patients with the same 
duration of onset and severity of BO. To the best of our knowledge, the relative 
number and frequency of infiltrated B cells have not been evaluated in the 
secondary lymphoid organs of patients with chronic GVHD, although high GC 
formation could occur because of increased BAFF levels58. GCs are specialized 
regions found in secondary lymphoid organs in which activated B cells undergo 
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diversification and affinity maturation that result in differentiation into both 
memory B cells and long-lived plasma cells that produce high-affinity, antigen-
specific, class-switched antibodies. GCs are required for a sustained humoral 
immune reaction to alloreactive antigens but also could result in the production of 
autoreactive antibodies and a dysregulated autoimmune response, which might 
be relevant in patients who have chronic GVHD symptoms59. Follicular B cells 
express LT-αβ, whereas follicular DCs express LTβR. One of the important 
consequences of the LT-LTβR interaction between these cells is the proper 
positioning of GC B cells and establishment of GC architecture. LT-LTβR 
signaling also enhances the follicular DC–B cell interactions by up-regulating 
expression of adhesion factors such as VCAM-1 on the follicular DCs. Inhibition 
of this interaction by use of the LTβR-Ig fusion protein prevents GC formation60. 
Treatment with LTβR-Ig had a direct effect on the symptoms of chronic GVHD, at 
least in part by blocking GC formation. These effects included an alleviation of 
pulmonary dysfunction. There was also a decrease in tissue-specific Ig levels in 
the sera. This confirms that inhibition of antibody secretion from post-GC B cells 
and plasmablasts elicits a positive response in animals that have pulmonary 
GVHD. The presence of IgG2c deposits in lung and liver further supports the 
notion that successful GC reactions that result in class switching are an important 
parameter in establishing lung and liver pathology. The fusion protein could work 
as a potential therapeutic agent for GVHD by causing a breakdown in GC 
architecture, resultant antibody production, and conversion of B cells into 
memory cells and plasmablasts. 
	   30	  
LTβR-Ig blocks both LTαβ and LIGHT, which is expressed on activated T cells 
and on B cells60. LIGHT has been demonstrated to have a role in the fibrosis, 
smooth muscle hyperplasia, and airway hyperresponsiveness associated with 
two murine models of chronic asthma. Pharmacologic inhibition of LIGHT 
resulted in better lung function, and this was linked to the reduced production of 
TGF-β and IL-13, cytokines involved in airway remodeling after injury61. The 
efficacy of LTβR-Ig as a chronic GVHD interventional strategy may be the result 
of multiple mechanisms of action, including disruption of GCs and antibody 
production. 
In summary, we have observed a requirement for B cells in development 
of chronic GVHD symptoms in lung and liver in a myeloablative conditioning 
model of allogeneic HCST. B cells, presumably via pathogenic antibody secretion 
by products of the GC reaction, including long-lived antibody-forming cells, play a 
causal role in modulating the physiology of the lung and pulmonary dysfunction. 
Our studies have therefore identified important immunologic processes that are 
involved in chronic GVHD and indicate that LTβR-Ig could be a potential clinical 
interventional strategy for prevention and therapy of chronic GVHD. 
 
Materials and Methods 
Mice 
C57Bl/6 (H2b) mice were purchased from the National Cancer Institute. B10.BR 
(H2k), BALB/c (H2d), and B6.129S2-Igh-6tm1Cgn/J mice on a C57Bl/6 
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background (referred to as µMT mice) were purchased from The Jackson 
Laboratory. BALB/c (m+s)IgMxJhD transgenic mice were bred at the University of 
Minnesota animal facility. Mice were housed in a specific pathogen-free facility 
and used with the approval of the University of Minnesota's institutional animal 
care committee. 
BM transplantation 
B10.BR recipients were conditioned with Cy on days −3 and −2 (120 mg · kg−1 · 
d−1 intraperitoneally). On day −1, recipients received TBI by x-ray (7.5 Gy). Donor 
BM was T-cell depleted with anti-Thy1.2 mAb followed by rabbit complement. T 
cells were purified from lymph nodes by incubation with phycoerythrin-labeled 
anti-CD19 (eBioscience), followed by anti-PE beads and depletion with a 
magnetic column (Miltenyi Biotec). On day 0, recipients received 10 × 106 BM 
cells with or without allogeneic splenocytes (0.75-1 × 106) or purified T cells (0.33 
× 106), as indicated. Weights of individual mice were recorded twice weekly. 
Where indicated, recipients in chronic GVHD groups were given murine LTβR-Ig 
or control murine MOPC21 provided by Biogen Idec at 200 µg per dose 
intraperitoneally every 3 days from days 28-52. 
Pulmonary function tests 
Anesthetized mice were weighed, and lung function was assessed by whole-
body plethysmography with the Flexivent system (SCIREQ) and analyzed with 
Flexivent Version 5.1 software. 
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Frozen tissue preparation 
All organs harvested were embedded in optimal cutting temperature compound, 
snap-frozen in liquid nitrogen, and stored at −80°. Lungs were inflated by infusion 
of 1 mL of optimal cutting temperature compound:PBS (3:1) intratracheally 
before harvest. 
Histology and trichrome staining 
Six-micrometer cryosections were fixed for 5 minutes in acetone and stained with 
H&E to determine pathology and with a Masson trichrome staining kit (Sigma-
Aldrich) for detection of collagen deposition. Histopathology scores were 
assigned as described previously. Collagen deposition was quantified on 
trichrome-stained sections as a ratio of area of blue staining to area of total 
staining by use of the Adobe Photoshop CS3 analysis tool. 
Immunohistochemistry 
Acetone-fixed 6-µm cryosections were immunoperoxidase stained with 
biotinylated mAbs for CD4, CD8, and B220 (BD Pharmingen). Stained sections 
were examined under 200× magnification, and images were captured with an 
Olympus BX51 microscope. Antibody-binding–positive cells were quantified by 
counting a 100-mm2 area for liver or obtaining a ratio of positive to total cells in a 
100-mm2 area for lung. 
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Immunofluorescence 
For Ig deposition, 6-µm cryosections were fixed with acetone, blocked with horse 
serum, and stained with either FITC-labeled anti–mouse Ig (BD Pharmingen) or 
goat anti–mouse IgM, goat anti–mouse IgG1, goat anti–mouse IgG2b, goat anti–
mouse IgG2c, or goat anti–mouse IgG3, followed by FITC-labeled donkey anti–
goat Ig (Jackson ImmunoResearch). For detection of tissue-specific serum 
antibodies, fixed cryosections of organs from a naive B10.BR mouse were 
incubated with sera from the BM-transplanted (BMT) recipients. Sections were 
incubated with FITC-labeled anti–mouse Ig. Confocal images were acquired on 
an Olympus FluoView500 confocal laser scanning microscope at 200× 
magnification, analyzed with FluoView 3.2 software (Olympus), and processed 
with Adobe Photoshop CS3 Version 9.0.2. Antibody deposition was quantified by 
scoring sections by use of a scale from 1-3. 
GC detection 
Fixed 6-µm spleen cryosections were stained with rat anti–mouse VCAM1 
followed by Cy3-labeled goat anti–rat, FITC-labeled rat anti–mouse IgM, and 
biotinylated peanut agglutinin (Vector Laboratories), followed by streptavidin Cy5. 
Confocal images were obtained as described in “Immunofluorescence.” 
Statistical analysis 
Survival data were analyzed by life-table methods, and actuarial survival rates 
are shown. Group comparisons were made by log-rank test statistics. Group 
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comparisons of cell counts and flow cytometry data were analyzed by Student 
t test. 
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Figure Legends 
 
Figure 1: Allogeneic transfer of BM and low concentrations of splenic cells 
in hosts treated with Cy/TBI-caused chronic GVHD and BO. B10.BR mice 
treated with 120 mg · kg−1 · d−1 Cy (day −3, −2) and lethally irradiated (day −1) 
were transplanted with BM alone or BM plus 0.75-1 × 106 splenocytes from 
C57Bl/6 mice. n = 10 mice/group. Weights of the animals (A) and survival (B) 
were tracked up to 60 days after transplantation. PFTs were performed on 
anesthetized animals at day 60 (C) and day 28 (D) after transplantation. Animals 
were artificially ventilated, and resistance, elastance, and compliance were 
measured as parameters of distress in lung function in animals receiving low-
dose splenocytes or T cells. Representative data from 3 individual experiments. 
**P < .01. 
Figure 2: Multiorgan disease in mice with chronic GVHD; immune 
infiltration and collagen deposition.(A) Tissues (lung, liver, tongue, salivary 
glands [SG], thymus, spleen, ileum, and colon) were harvested at day 60 after 
transplantation and stained with H&E to determine pathology. Bright-field images 
were captured at 100× magnification with an Olympus BX51 microscope. (B) 
Inflammation, immune infiltration, and parenchymal changes were scored with a 
cumulative scoring system. (C) Collagen deposition was determined with a 
Masson trichrome staining kit; blue indicates collagen deposition. (D) Collagen 
deposition was quantified as a ratio of blue area to total area of tissue. 
Quantification was performed with the analysis tool in Photoshop CS3. Data from 
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2 individual experiments were pooled to obtain pathology scores; n = 12. *P < 
.05; **P < .01; ***P < .005. 
 
Figure 3: CD4+ T-cell and B220+ B-cell infiltration is seen in lungs and livers 
of transplanted animals. Liver and lung tissues were harvested at day 60 after 
transplantation from animals receiving BM only and BM plus splenocytes (BM + 
spleen) and analyzed by immunohistochemistry and methyl blue counterstaining. 
Representative images from 3 individual experiments are shown for CD4 (A) and 
B220 (D). Images were captured with a bright-field microscope at 200× 
magnification. For lung, infiltration was quantified by obtaining a ratio of CD4+ (B) 
or B220+ (E) cells to total cells in a 100-mm2 field of view under the microscope. 
Shown is an average of the count from 4 representative fields. For liver, CD4 (C) 
and B220 (F) cell infiltration was quantified by counting the number of antibody 
binding–positive cells and obtaining an average of counts from 4 representative 
fields. n = 6. *P < .05; **P < .01; ***P < .005. 
 
Figure 4: Antibody deposition detected in target areas of lung and liver in 
diseased animals.Six-micrometer sections of frozen lung and liver tissues 
harvested at day 60 after transplantation were analyzed by immunofluorescence. 
Tissues were incubated with FITC-conjugated anti-mouse Ig. (A) Representative 
images for lung and liver from 3 individual experiments. n = 8. (B) Ig deposition 
was quantified on a 0-3 scale to determine the amount of antibody in the tissues. 
(C) Serum from animals given BM only and animals given BM plus splenocytes 
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was collected at day 60 after transplantation and incubated with healthy B10.BR 
lung and liver tissue followed by FITC-conjugated anti-mouse Ig to detect the 
presence of tissue-specific antibodies in the serum of diseased animals. White 
arrows depict areas of Ig deposition. Fluorescence was detected with an 
Olympus FluoView 500 confocal laser scanning microscope at a magnification of 
200×. 
 
Figure 5: Animals receiving B cell–deficient BM show a decrease in 
pathology. B10.BR recipients were transplanted with WT BM or BM from µMT 
knockout mice with or without WT T cells. (A) At 60 days after transplantation, 
mice were anesthetized and artificially ventilated to measure pulmonary function 
parameters. (B) Collagen deposition was quantified from trichrome-stained 
samples as a ratio of blue area to total area of tissue. Quantification was 
performed with the analysis tool in Photoshop CS3. (C) Lung and liver tissues 
were harvested, and 6-µm frozen sections were stained with FITC-conjugated 
anti–mouse Ig for antibody deposition within the tissues. White arrows denote 
areas of Ig deposition. Images shown are representative images of 3 individual 
experiments; n = 4. *P < .05; ***P < .005; P = .4066 for lung BM (µMT) only vs 
BM (µMT) + T cells; P = .2860 for liver BM (µMT) only vs BM (µMT) + T cells. 
 
Figure 6: Secreted antibody is required for pulmonary dysfunction in 
animals with chronic GVHD. (A) B10.BR mice were transplanted with BM ± 
splenocytes from WT or (m+s)IgMxJhD BALB/c mice and anesthetized at day 60 
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after transplantation for PFTs. Resistance, compliance, and elastance were 
measured; n = 8. (B) Collagen deposition was quantified from trichrome-stained 
samples as a ratio of blue area to total area of tissue. Quantification was 
performed with the analysis tool in Photoshop CS3. (C) Infiltration of CD4+ cells 
in the lung and liver of transplanted mice. (D) Lung and liver tissues were 
harvested, and 6-µm frozen sections were stained with FITC-conjugated anti-
mouse Ig for antibody deposition within the tissues. White arrows denote areas of 
Ig deposition. Representative image from 2 independent experiments; n = 8. *P < 
.05; **P < .01; ***P < .005. 
Figure 7: Disruption of GC formation by LTβR-Ig treatment reduces lung 
dysfunction and chronic GVHD organ tissue fibrosis. B10.BR recipients were 
transplanted as per Figure 1. A cohort of animals receiving BM + splenocytes 
were treated with 200 µg of murine LTβR-Ig or the control Ab, murine MOPC21, 
every 3 days beginning on day 28 after transplantation until day 52. (A) Spleen 
tissue harvested from these animals at day 60 was analyzed by 
immunofluorescence for GC structures. GCs were detected by colocalization of 
IgM (green), VCAM-1 (blue), and peanut agglutinin (red); merged images show 
overlap (white) to discriminate GC. White arrows highlight GC. Images were 
captures with an Olympus FluoView 500 confocal laser scanning microscope at 
100× magnification; n = 5. (B) The size of the GC was quantified by measuring 
the area of peanut agglutinin staining in Photoshop C3. (C) Frequency of GCs 
was quantified by counting the number of GCs in 1 mm2 of spleen section. (D) 
PFTs were performed on anesthetized animals on day 60 after transplantation to 
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measure lung function. (E) Animals treated with LTβR-Ig and MOPC21 were 
examined for fibrosis in the lung and liver. (F) Presence of deposited lung and 
liver tissue–specific antibodies in animals treated with LTβR-Ig and MOPC21 was 
determined by immunofluorescence by staining with FITC-conjugated anti–
mouse Ig. White arrows depict Ig deposition. Images were captured at 200× 
magnification and are representative of 2 individual experiments; n = 5. *P < .05; 
**P < .01. 
Supplemental Figure 1: Increased peripheral pulmonary pathology 
associated chronic GVHD. Representative image of three independent 
experiments, hematoxylin and eosin stained lung tissue from chronic GVHD 
group taken day 60 post transplant. * denotes protein exudation, closed arrow 
denotes macrophage infiltration. Image was captured at 200x magnification. 
Representative image from 3 experiments. 
Supplemental Figure 2: sections of frozen lung and liver tissues harvested at 
day 28 after transplantation and stained with Hematoxylin and Eosin to determine 
pathology. Inflammation, immune infiltration and parenchymal changes were 
scored, using a cumulative scoring system used previously26, n=4 per group. * 
P<0.05, *** P<0.005. 
Supplemental Figure 3: Deposition of IgG2c in the lung of mice with 
chronic GVHD compared to BM only controls. 6um sections of frozen lung 
tissues harvested at day 60 after transplantation were analyzed by 
immunofluorescence. Tissues were incubated with either goat anti-mouse IgM, 
	   40	  
IgG1, IgG2b, IgG2c or IgG3 and followed by donkey anti-goat Ig-FITC. White 
arrow denotes area of Ig deposition. Representative images for lung from two 
individual experiments are displayed. 
Supplemental Figure 4 : Decreased µMT pathological scores. 6um sections 
of frozen lung and liver tissues harvested at day 60 after transplantation and 
stained with Hematoxylin and Eosin to determine pathology. Inflammation, 
immune infiltration and parenchymal changes were scored, using a cumulative 
scoring system used previously26. Representative scores n=5 per group. * 
P<0.05; p=0.3228 for lung BM (µMT) versus BM (µMT)+T cells; p=0.2893 for 
liver BM (µMT) versus BM (µMT)+T cells. 
Supplemental Figure 5: Tregs from (m+s)IgMxJhD Balb/c mice are able to 
suppress CD4+ T cells at the same level as WT Balb/c Tregs. T cells from 
Thy1.1 Balb/c mice were labeled with CFSE and mixed with different proportions 
of CD4+ CD25+ T cells from either WT Balb/c (WT) or (m+s)IgMxJhD (m+s) with 
0.25 mg/mL of anti-CD3 in complete DMEM. After 4 days, division of CD4+ 
Thy1.1+ cells was analyzed by dilution of CFSE on the BD LSRFortessa. 
Supplemental Figure 6: Pathological scores of mice transplanted with 
(m+s)IgMxJhD BM have elevated pathology scores compared to BM only. 
6um sections of frozen lung and liver tissues harvested at day 60 after 
transplantation and stained with Hematoxylin and Eosin to determine pathology. 
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Inflammation, immune infiltration and parenchymal changes were scored, using a 
cumulative scoring system used previously26. Representative scores n=4 per 
group. * P<0.05; p=0.4881 for lung (m+s)IgMxJhD BM only versus 
(m+s)IgMxJhD BM+spleen; p=0.6704 for liver (m+s)IgMxJhD BM only versus 
(m+s)IgMxJhD BM+spleen. 
Supplemental Figure 7: Pathological scores of mice treated with LTbR-Ig 
demonstrate infiltration in treated mice. 6um sections of frozen lung and liver 
tissues harvested at day 60 after transplantation and stained with Hematoxylin 
and Eosin to determine pathology. Inflammation, immune infiltration and 
parenchymal changes were scored, using a cumulative scoring system used 
previously26. Representative scores n=4 per group. * P<0.05; p=0.2029 for lung 
BM+spleen MOPC21 versus BM+spleen LTbR-Ig; p=0.5543 for liver BM+spleen 
MOPC21 versus BM+spleen LTbR-Ig. 
Supplemental Figure 8: Increased Germinal Center size and frequency on 
Day 28 post transplantation. 6um sections of frozen lung and liver tissues 
harvested on day 28 after transplantation and stained with Biotin-PNA and FITC-
IgM followed by SA-PE. The size of the GC was quantified by measuring the 
area of PNA staining in Photoshop C3. Frequency of the GC was quantified by 
counting the number of GCs in 1 mm2 of spleen section, representative 
experiment n=4. * P<0.05, *** P<0.005 
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Chapter III: Increased T follicular helper cells and germinal center B cells 
are required for chronic GVHD and bronchiolitis obliterans 
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Chronic graft-versus-host disease is a leading cause of morbidity and mortality 
after allogeneic hematopoietic stem cell transplantation. Having shown that 
germinal center (GC) formation and immunoglobulin deposition are required for 
multiorgan system chronic GVHD and associated bronchiolitis obliterans 
syndrome (BOS) in a murine model, we hypothesized that T follicular helper (Tfh) 
cells are necessary for chronic GVHD by supporting GC formation and 
maintenance. We show that increased frequency of Tfh cells correlated with 
increased GC B cells, chronic GVHD, and BOS. Although administering a highly 
depletionary anti-CD20 monoclonal antibody (mAb) to mice with established 
chronic GVHD resulted in peripheral B-cell depletion, B cells remained in the 
lung, and BOS was not reversed. BOS could be treated by eliminating production 
of interleukin-21 (IL-21) by donor T cells or IL-21 receptor (IL-21R) signaling of 
donor B cells. Development of BOS was dependent upon T cells expressing the 
chemokine receptor CXCR5 to facilitate T-cell trafficking to secondary lymphoid 
organ follicles. Blocking mAbs for IL-21/IL-21R, inducible T-cell costimulator 
(ICOS)/ICOS ligand, and CD40L/CD40 hindered GC formation and chronic 
GVHD. These data provide novel insights into chronic GVHD pathogenesis, 
indicate a role for Tfh cells in these processes, and suggest a new line of therapy 
using mAbs targeting Tfh cells to reverse chronic GVHD. 
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Introduction 
Chronic graft-versus-host disease is a major obstacle following allogeneic 
hematopoietic stem cell transplantation62, 63. Clinically representative models 
have increased our understanding of acute GVHD, but the dearth of relevant 
chronic GVHD murine models has limited our ability to interrogate its underlying 
pathophysiology64, 65. However, recent work with a novel murine model of 
multiorgan chronic GVHD that highlights lung pathology with the development of 
bronchiolitis obliterans syndrome (BOS) has provided new insight into research 
on chronic GVHD24, 36. 
Even though the exact mechanism of chronic GVHD is unknown, B cells 
and pathogenic antibody production are clearly implicated in both human and 
mouse models. Patients diagnosed with chronic GVHD had elevated soluble B-
cell activating factor and increased proportions of pre-germinal center (GC) B 
cells and post-GC plasmablasts19. Furthermore, male patients who received 
grafts from female donors had an increase in antibody response to H-Y minor 
histocompatibility antigens, which correlated with chronic GVHD18. In addition, we 
have shown that B cells are required to induce chronic GVHD and associated 
BOS in this clinically relevant murine model24. Not only was the presence of B 
cells necessary but the development of tissue fibrosis was dependent on 
secretion of class-switched antibody. These data suggest that B-cell activation 
and maturation is necessary for chronic GVHD progression. 
The ability of B cells to create high-affinity antibodies is dependent on the 
GC reaction and extrafollicular B cells. Once B cells recognize cognate antigen, 
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they can undergo somatic hypermutation and class switching with the aid of CD4 
T cells in the B-T cell junction within secondary lymphoid organs. T cells are 
required to provide survival signals to B cells that are rapidly making random 
mutations to the complementary determining regions in the immunoglobulin (Ig) 
genes. This results in the negative selection of poor-affinity antibodies, while 
selecting for those B cells with mutations that increase antibody affinity. B cells 
that produce high-affinity class-switched antibodies are able to activate immune 
responses and, in the case of chronic GVHD, cause severe damage to the target 
tissues by activating complement or antibody-dependent cell-mediated 
cytotoxicity. 
We sought to investigate the role of T follicular helper (Tfh) cells in the 
genesis of chronic GVHD in order to develop new interventions. Previously, we 
defined the role of antibody production by bone marrow (BM)-derived B-cell 
progeny in the initiation and maintenance of chronic GVHD in this clinically 
relevant murine model24. The ability of B cells to produce class-switched 
antibodies and the need for lymphotoxin β receptor signaling in the GC was 
highlighted, clearly defining the importance of GC maturation during chronic 
GVHD. Tfh cells are a subset of CD4+ T cells that are located in the B-cell follicle 
and express the transcription factor Bcl6 along with high levels of the chemokine 
receptor CXCR5 and programmed cell death protein-1 (PD-1)66. These cells 
support the generation of GCs by providing signaling through interleukin-21 (IL-
21), inducible T-cell costimulator (ICOS), and CD4026, 67-69. Having previously 
shown that B-cell production of class-switched antibody is necessary for chronic 
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GVHD, we hypothesized that maintenance of the GC by Tfh cells is necessary 
for the progression of chronic GVHD and associated BOS. Genetic deletions and 
interventional therapies were used to study the importance of Tfh cell signaling of 
GC B cells during murine chronic GVHD. 
 
Results 
Increased Tfh cell frequency during chronic GVHD 
Previously, we demonstrated that mice with chronic GVHD have larger 
and more frequent GCs in the spleen compared with BM only (non-chronic 
GVHD) mice.24 Therefore, we examined the presence of splenic Tfh cells in 
chronic GVHD mice because Tfh cell support is necessary for GC formation36, 70, 
71. Spleens harvested from mice with chronic GVHD demonstrated an increased 
presence of CD4+ cells in peanut agglutinin–positive GC areas compared with 
non-GVHD mice, co-localizing to regions of high PD-1 expression (Figure 1A). 
Localization of CD4+ cells to the GC by the chemical gradient chemokine ligand 
CXCL13 binding with its receptor CXCR5 is a hallmark of Tfh cells72. During 
chronic GVHD, CD4 localization was associated with increased GC size and GC 
B cells, denoted by GL7 staining (Figure 1B; see also Figure 1E). Flow cytometry 
of purified splenocytes from BM only non-chronic GVHD and chronic GVHD mice 
showed a significant decrease in the proportion of B1a, B1b, CD23+, IgM+, and 
IgD+ follicular B cells (Figure 1C). Even though there are fewer follicular B cells, 
there is an increase in the frequency of B cells entering the GC. In addition, there 
was a twofold increase in the frequency of splenic Tfh cells, defined as PD-
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1hiCXCR5+ CD4 T cells in chronic GVHD mice compared with non-chronic GVHD 
mice (Figure 1D), which correlated with a twofold increase in the percentage of 
GL7+, Fas+, and CD38− GC B cells (Figure 1E). 
Anti-CD20 therapy does not prevent the development of chronic GVHD 
Rituximab therapy has been used as an attractive treatment for some 
patients with chronic GVHD to eliminate pathogenic B cells. We sought to 
determine the therapeutic effect of anti-CD20 in our mouse model of chronic 
GVHD, which is dependent on B-cell activation and GC reaction. B10.BR mice 
were transplanted with wild-type (WT) B6 BM cells and WT B6 T cells and 
allowed to develop chronic GVHD over 28 days, at which point mice were given 
anti-CD20 to deplete B cells. When analyzed on day 60, >98% of the splenic B 
cells were depleted (Figure 2B). However, mice still developed chronic GVHD. 
PFTs demonstrated decreased functional capacity of the lungs as evidenced by 
increased resistance and elastance and decreased compliance similar to 
irrelevant mAb–treated chronic GVHD mice (Figure 2A). Furthermore, anti-
CD20–treated chronic GVHD mice had increased collagen deposition 
surrounding the bronchioles, consistent with BOS compared with BM only mice 
(Figure 2C). Tissues were analyzed for the deposition of IgG2c antibody. 
Compared with BM only controls and despite peripheral B-cell depletion by anti-
CD20 mAb, chronic GVHD mice given anti-CD20 mAb had increased IgG2c, but 
not the isotype of anti-CD20 mAb (IgG1) (Figure 2D and supplemental Figure 1). 
We examined potential reasons why anti-CD20 therapy was not able to decrease 
development of BOS and chronic GVHD. First, plasma cells (CD138+ CD19lo), 
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which do not express CD20, were significantly increased in the BM and spleen of 
mice treated with anti-CD20 mAb (Figure 2E and data not shown). This suggests 
that depletion therapy increases selection of CD20-deficient further differentiated 
antibody-producing cells. Next, anti-CD20 therapy was unable to deplete 
CD19+ B cells within the target organs, including the lung (Figure 2F). Finally, 
even though there was a significant depletion of total B cells, there was a 
threefold increase in the relative frequency of GC B cells in the B-cell 
compartment of mice treated with anti-CD20 therapy compared with irrelevant 
mAb–treated chronic GVHD control mice (P < .05; data not shown). The increase 
in frequency highlights the relative resistance of GC B cells to B-cell–depleting 
therapy73. Thus, B-cell depletion therapy for treatment of active chronic GVHD 
had little effect on the progression of the disease likely because of the inability to 
deplete all GC B cells. 
 
T cell Trafficking to the B-cell follicle by the chemokine receptor CXCR5 is 
necessary in chronic GVHD 
Trafficking of Tfh cells to the B-cell zone is dependent on the expression 
of the chemokine receptor CXCR5, which binds CXCL13 secreted by follicular 
dendritic cells. Without CXCR5, Tfh cells are unable to localize to the B-cell 
follicle and cannot interact with GC B cells. To determine the requirement for 
such Tfh cell migration during chronic GVHD, we transplanted mice with T cells 
deficient in CXCR5. Compared with positive control mice with chronic GVHD, 
which received WT BM and WT T cells, recipients of WT BM cells with CXCR5 
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KO T cells had PFTs that were significantly improved and comparable to BM-only 
controls (Figure 3A). In recipients given CXCR5 KO T cells, there was a 
significant decrease in the amount of Ig found in the lungs of these mice (Figure 
3B-C), and collagen surrounding the bronchioles was significantly decreased as 
demonstrated by trichrome staining (Figure 3D-E). Together, these data 
demonstrate that CXCR5 expression on donor T cells is needed for chronic 
GVHD associated with BOS. 
 
IL-21 is a required cytokine for the development of chronic GVHD 
Tfh cells are able to drive GC reactions by multiple mechanisms, including 
cell-to-cell contact and secretion of key cytokines. IL-21 is a major cytokine 
produced by Tfh cells. Although IL-21 is not essential for GC formation, it is 
important for the production of memory B cells with high-affinity antibody 
production74. Therefore, we investigated the role of IL-21 in chronic GVHD and its 
possible requirement for the production of class-switched IgG that is deposited in 
chronic GVHD organs. Mice were transplanted with WT BM and either no T cells 
or WT or IL-21 KO splenocytes. Recipients of IL-21 KO splenic T cells did not 
develop symptoms of BOS as demonstrated by PFTs (Figure 4A). A decrease in 
the GC sizes (Figure 4B) was also seen. Deposition of Ig in the tissues was 
restored to healthy control levels (Figure 4C), leading to a twofold decrease in 
collagen (Figure 4D) in recipients of IL-21 KO splenic T cells compared with 
chronic GVHD controls. There was a two-fold decrease in frequency of splenic 
Tfh cells; moreover, the frequency of GC B cells was significantly decreased 
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compared with the recipients of WT splenic T cells (Figure 4E-F). Profibrotic 
effects of IL-21 may contribute to chronic GVHD and BOS75. To determine the 
extent to which the profibrotic vs B-cell activating functions of IL-21 accounted for 
improved PFTs, we transplanted mice with BM from WT or IL-21R KO donors 
with or without WT splenic T cells. Compared with recipients of WT BM and WT 
splenic T cells, mice transplanted with the IL-21R KO BM and WT splenic T cells 
had significantly improved PFTs (Figure 5A) and reduced GC area (Figure 5B) 
associated with reduced frequencies of PD-1hiCXCR5+ Tfh cells (Figure 5C) and 
GL7+CD38lo GC B cells (Figure 5D) that was not different from BM only no 
chronic GVHD controls. Concordant with these findings, Ig (Figure 5E-F) and 
collagen (Figure 5G-H) were detected at levels less than that found in BM only 
controls. Together these data demonstrate a requirement for both donor T-cell IL-
21 production and donor BM IL-21R expression in generating Tfh cells, GCs, and 
chronic GVHD with BOS. 
Blocking signaling from ICOS and CD40 has a therapeutic benefit in 
chronic GVHD 
ICOS and CD40 signals are required for GC formation69. ICOS is highly 
expressed on Tfh cells and is necessary for secretion of IL-21 following 
engagement with ICOS ligand–expressing B cells. CD40 is expressed on B cells 
in the GC, and signaling through CD40 by CD40 ligand–expressing T cells is 
necessary for the survival of B cells in the GC. Disruption of ICOS/ICOS ligand 
and CD40/CD40 ligand has been shown to decrease antibody formation in 
murine lupus models and to be important in the progression of acute GVHD76, 77. 
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To determine whether ICOS and CD40 are necessary signals in chronic GVHD, 
mice with WT BM and splenic T cells were administered anti-ICOS– and anti-
CD40 ligand–blocking mAbs beginning 28 days after transplantation, when 
chronic GVHD has been established24. Mice given either anti-ICOS or anti-CD40 
ligand blocking mAbs had PFTs comparable to those of BM only controls (Figure 
6A). Mice treated with anti-ICOS or anti-CD40L had a 95% reduction in GC 
formation (Figure 6B). The decrease in overall size of GCs correlated with a 
threefold reduction in Tfh cells and GC B cells present in the spleen (Figure 6C-
D). Furthermore, IgG2c deposition surrounding the bronchioles in the lung was 
decreased (Figure 6E-F). Finally, the mice treated with anti-ICOS or anti-CD40L 
mAb did not have increased collagen surrounding the bronchioles (Figure 6G-H). 
Consistent with anti-ICOS–blocking mAb data, PFTs in recipients of ICOS KO vs 
WT T cells indicated normalization compared with BM only controls 
(supplemental Figure 2). These data indicate that the ICOS and CD40 signaling 
in the GC is necessary for the development of chronic GVHD. 
Therapeutic effect of IL-21 mAb in mice with chronic GVHD and BOS 
Blocking cytokine signaling was shown to be effective in many 
autoimmune diseases, including systemic lupus erythematous and rheumatoid 
arthritis78, 79. To determine whether the effects of neutralizing IL-21 would be a 
potential therapeutic for the progression of chronic GVHD and establishment of 
BOS, mice were transplanted with WT BM and WT splenic T cells and were 
treated with irrelevant or anti-IL-21 neutralizing mAb starting on day 28 after BM 
transplant. Mice treated with anti-IL-21 mAb demonstrated normalized pulmonary 
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function comparable to that in BM only recipients (Figure 7A). Anti-IL-21 mAb 
was effective at decreasing the frequency of GC B cells and Tfh cells in the 
spleen (Figure 7B-C). By blocking IL-21 in the chronic GVHD mice, we were able 
to limit the GC reaction and Ig deposition in the lung (Figure 7D). Finally, there 
was no increase in collagen deposition in mice treated with anti-IL-21 mAb 
(Figure 7E). These data demonstrate a novel potential therapy for the treatment 
of chronic GVHD and associated BOS. 
 
 
Discussion 
In this study, we defined a novel role of Tfh cells in the activation of GC B 
cells in the production and deposition of pathologic Ig and collagen, ultimately 
causing BOS and multiorgan system chronic GVHD. Although chronic GVHD B 
cells are activated and primed for survival via B-cell activating factor and BCR-
associated signaling pathways80, the direct mechanism underpinning B-cell 
activation has yet to be clearly defined. By using a preclinical chronic GVHD 
model, our data strongly suggest that donor T-cell–derived Tfh cells are 
necessary for the activation of donor BM–derived B cells that differentiate into 
GC B cells, resulting in Ig deposition in BOS lesional tissue. Consistent with this 
notion, preliminary data indicate that recipients of either BM or T cells from bcl6 
KO donors are unable to cause chronic GVHD (data not shown), pointing to the 
requirement for Tfh cells and GC B cells in chronic GVHD generation and/or 
maintenance under these conditions. The increase in GC size (Figure 1A-B) is 
independent of the number and frequency of follicular B cells present during 
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chronic GVHD (Figure 1C) and, in fact, CD19+B220+CD5hi B1a cells (that 
produce broadly reactive natural IgM) and CD19+B220+CD5lo B1b B cells (that 
produce adaptive IgG antibody, especially to T-cell–independent type 2 antigens) 
are significantly decreased in chronic GVHD mice. Together, these data indicate 
that there is not a general increase in the B-cell population, but there is a 
selective increase in the frequency of GC B cells and GC number per area. 
Although splenic B-cell and GC populations were largely depleted by anti-CD20 
mAb therapy for established chronic GVHD, there was no impact on chronic 
GVHD BOS (Figure 2). Possible explanations include inadequate B-cell depletion 
in chronic GVHD target organs (Figure 2F) and/or failure to deplete preformed 
plasma cells residing in the BM (Figure 2E). The increased activation state of GC 
B cells during chronic GVHD has the potential to make monoclonal cellular 
depletion therapies less effective, as seen in other autoimmune disorders17, 81. 
The production of class-switched antibodies requires the ability of T cells to 
localize to the GC and provide survival signals to B cells during chronic GVHD. 
Interruption of trafficking of T cells to the B-cell follicle by CXCR5 was sufficient 
for preventing GC response and preventing chronic GVHD (Figure 3). Expression 
of CXCR5 is a hallmark of Tfh cells, and without this essential chemokine 
receptor, GCs failed to increase posttransplant during conditions that otherwise 
were conducive to chronic GVHD generation. Di Carlo et al82 demonstrated that 
cardiac allo-rejection was highly associated with production of CXCL13 and 
increased GC formation. 
	   69	  
Robust GC reactions during chronic GVHD were dependent on the 
production of IL-21 from donor T cells (Figures 4 and 5). Tfh cells are dependent 
on the antigen-presenting function of B cells in the GC for maintenance83. In 
chronic GVHD, a decrease in IL-21 could potentially play multiple roles 
independent of Tfh cell involvement, including increase in induced T regulatory 
cells84, possibly including T follicular regulatory cells. For example, IL-21 is 
important in the production of higher-affinity antibodies by stabilizing the 
expression of Bcl668. This is consistent with our findings that IL-21 signaling in B 
cells is necessary to produce Ig that is deposited in the lung and associated with 
BOS (Figure 5). Our data using IL-21 KO T cells, IL-21R KO BM cells, and 
neutralizing anti-IL-21 mAb collectively indicate that the IL-21/IL-21R pathway is 
a promising target for therapeutics. Together, these data suggest that naïve 
donor T cells differentiate into Tfh cells that support GC formation after 
alloactivation, resulting in the upregulation of CXCR5, ICOS, CD40L, and IL-21 
production, which then work in concert to migrate to secondary lymphoid organs 
and drive GC B-cell differentiation and GC formation. 
ICOS and CD40 signaling are required for the establishment of GCs and 
have been demonstrated to eliminate GC reactions upon blockade82, 85. The 
presence of Tfh cells and the stability of GC are contingent upon ICOS and CD40 
expression85 and are necessary for the progression of chronic GVHD in our 
model (Figure 6 and supplemental Figure 2). ICOS could also be necessary for 
T-cell activation independent of GCs, as demonstrated when ICOS KO T cells 
are used in acute GVHD76. By using either blocking anti-ICOS or anti-CD40 
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ligand mAbs, we have demonstrated that disease progression is prevented or 
even reversed, revealing that the maintenance of GCs is essential in chronic 
GVHD. Although data presented here suggest that ICOS, CD40, and IL-21 
blockade are effective in treating chronic GVHD associated with the dampening 
of the Tfh cell response, alternative mechanisms may exist. For example, it has 
previously been demonstrated that anti-IL-21 can increase peripheral-derived T 
regulatory cells84. The increase in T regulatory cells may dampen the GC 
response. Moreover, alloactivated T effector cells might directly contribute to 
tissue injury and work alone or in concert with Tfh cells to cause chronic GVHD. 
By blocking IL-21, ICOS, or CD40L signaling, T-cell proliferation, survival, or 
effector function may be compromised, resulting in reduced tissue injury and 
chronic GVHD, independent of the requirement for Tfh cells in the chronic GVHD 
process. 
The use of this BOS murine model of chronic GVHD should be readily 
translatable to human chronic GVHD. The National Institutes of Health 
consensus group defined the diagnosis of BOS as a pathognomonic symptom of 
lung chronic GVHD86. By using clinically relevant functional, histopathologic, and 
immunologic markers of chronic GVHD as readouts, we can confirm the chronic 
GVHD disease state. Moreover, Srinivasan et al24 demonstrated that the BOS 
model represents a multiorgan syndrome that is consistent with human chronic 
GVHD pathology. Finally, prior to interventions, we established chronic GVHD 
instead of taking a prophylactic approach. This is consistent with diagnosis and 
starting patients on treatment following allogeneic hematopoietic stem cell 
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transplantation. However, it is important to point out that there are several 
potential adverse events associated with the proposed therapeutics. For 
example, blocking IL-21, ICOS, or CD40L with mAbs might increase either T-cell 
responsive infections or the rate of leukemia relapse as a result of dampening of 
peripheral immune surveillance mechanisms. Finally, our discovery that Tfh cells 
are upregulated in murine chronic GVHD warrants investigation of this cell 
population in the peripheral blood87 of chronic GVHD patients. If correlations are 
noted with chronic GVHD onset or severity, Tfh cells could be targeted, as we 
have done in this study, which may prove useful for treating or perhaps 
preventing chronic GVHD in the clinic. 
 
Materials and Methods 
Mice 
C57Bl/6 (B6; H2b) mice were purchased from the National Cancer Institute. 
B10.BR (H2k), CXCR5−/−, and ICOS−/− B6 knockout (KO) mice were purchased 
from Jackson Laboratories. B6 IL-21−/− and IL-21 receptor (IL-21R)−/− KO mice 
were bred at the University of Minnesota animal facility. Mice were housed in a 
specific pathogen-free facility and used with the approval of the University of 
Minnesota institutional animal care facility. 
	   72	  
Bone marrow transplant and therapeutic intervention 
B10.BR recipients were conditioned with Cy on days −3 and −2 (120 mg/kg per 
day intraperitoneally). On day 1, recipients received total-body irradiation by x-ray 
(8.3 Gy). B6 donor BM was T-cell depleted with anti-Thy1.2 monoclonal antibody 
(mAb) followed by rabbit complement. T cells were purified from spleens by 
incubation with phycoerythrin-labeled anti-CD19 (eBioscience), followed by anti-
phycoerythrin beads and depletion with a magnetic column (Miltenyi-Biotec). On 
day 0, recipients received 10 × 106 T-cell–depleted BM cells with or without 
allogeneic spleen cells (0.75 × 106 to 1 × 106) or purified splenic T cells (0.1 × 
106), as indicated. Weights of individual mice were recorded each week. Where 
indicated, recipients in chronic GVHD groups were given anti-CD20 (250 µg per 
animal every 2 weeks; clone 18B12, IgG2a; kindly provided by Biogen Idec), anti-
IL-21 (250 µg per animal twice a week; clone Ch268.5.1, mIgG1, kindly provided 
by Novo Nordisk), anti-ICOS (200 µg per animal three times a week; clone 
7E.17G9.G1, rIgG2b), or anti-CD40L (200 µg per animal twice a week; clone 
MR1, hamster IgG), or irrelevant isotype antibody as previously reported.  
Pulmonary function tests 
Pulmonary function tests (PFTs) were performed as described.6 Briefly, 
anesthetized mice were weighed, and lung function was assessed by whole-body 
plethysmography using the Flexivent system (Scireq) and was analyzed by using 
the Flexivent software version 5.1. 
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Frozen tissue preparation 
All organs harvested were embedded in Optimal Cutting Temperature 
compound, snap-frozen in liquid nitrogen, and stored at −80° centigrade. Lungs 
were inflated by infusing 1 mL of optimum cutting temperature 
compound:phosphate-buffered saline (3:1) intratracheally prior to harvest. 
Trichrome staining 
Cryosections (6 µm) were fixed for 5 minutes in acetone and stained with 
Masson’s trichrome staining kit (Sigma) for detection of collagen deposition. 
Collagen deposition was quantified on trichrome-stained sections as a ratio of 
area of blue staining to area of total staining by using the Adobe Photoshop CS3 
analysis tool (Adobe Systems) 
Immunofluorescence 
For Ig deposition, 6-µm cryosections were fixed with acetone and then blocked 
with horse serum and streptavidin-biotin blocking kit (Vector) and stained with 
fluorescein isothiocyanate (FITC)-labeled anti-mouse-Ig (BD Pharmingen) or 
goat-anti-mouse-IgG2c followed by FITC-donkey-anti-goat Ig (Jackson 
ImmunoResearch). Antibody deposition was quantified by area of Ig staining per 
100-µm section. Fixed 6-µm spleen cryosections were stained with rhodamine-
peanut agglutinin (Vector Laboratories), anti-PD-1 FITC, anti-GL7 FITC, anti-CD4 
biotin or anti-CD19 biotin followed by Cy5-conjugated streptavidin to detect the 
presence of B cells and T cells in the GC. Confocal images were acquired on an 
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Olympus FluoView500 Confocal Laser Scanning Microscope at ×200, analyzed 
by using FluoView3.2 software (Olympus), and processed with Adobe Photoshop 
CS3, version 9.0.2. 
Flow Cytometry 
For flow cytometric analysis of Tfh cells and GC B cells, single-cell suspensions 
from spleens or the peritoneal cavity were obtained and labeled with anti-CD4, 
anti-CXCR5, anti-PD-1, anti-CD19, anti-GL7, anti-CD38, anti-IgM, anti-IgD, anti-
CD23, or anti-CD5 (eBioscience). Cells were analyzed on a BD LSRFortessa cell 
analyzer. 
Statistics 
Group comparisons of cell counts and flow cytometry data were analyzed by 
Student t test. 
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Figure Legends 
Figure 1: Increased Tfh in chronic GVHD. B10.BR mice were transplanted with 
BM only or BM and splenic T cells from B6 donor mice and spleens were 
harvested on D60. A) Representative spleens harvested from BM only and 
BM+spleen (S) mice on day 60 showing CD4 (Blue), PD-1 (Green) and PNA 
(Red) or B) CD19 (Blue), GL7 (Green) and PNA (Red). Arrows highlight germinal 
center areas. C) Composition of B cells in the spleen and the peritoneal cavity. 
D) Frequency of Tfh cells and E) GC B cells. * P < 0.05, *** P < 0.001.  
 
Figure 2: B cell depletion by anti-CD20 therapy is not sufficient to prevent 
chronic GVHD and associated BOS. Chronic GVHD was established in 
B10.BR mice transplanted with WT B6 BM and WT B6 spleen cells and mice 
were treated with anti-CD20 or irrelevant mouse IgG1 antibody starting D28-56. 
A) Pulmonary function tests for mice treated with irrelevant or anti-CD20 
antibody. B) Number of B cell purified from the spleens of mice on D56. C) 
Trichrome deposition and D) Ig deposition in the lung of mice harvested on D56. 
E) Representative images of frozen lung tissues stained with anti-CD19 FITC 
and DAPI. Representative data from 2 experiments n=8 mice per group. ** P < 
0.01; *** P < 0.001. 
 
Figure 3: Chemokine receptor CXCR5 on donor mature T cells is necessary 
for chronic GVHD. B10.BR mice were transplanted with WT B6 BM and WT B6 
T cells or B6 CXCR5 KO T cells. A) Mice were evaluated for pulmonary function. 
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B) Lung sections were stained with FITC conjugated anti-mouse Ig and the area 
of Ig deposition was measured C) representative images. D) Lungs of mice were 
stained for Trichrome and the ratio of collagen stain to total stain was measured 
surrounding the bronchioles E) representative images. Representative data from 
3 experiments with n=8 mice per group. * P < 0.05; ** P < 0.01; *** P < 0.001. 
 
Figure 4: IL21 production from donor T cells is required for chronic GVHD 
pathology. B10.BR mice were transplanted with WT B6 BM and splenocytes 
from either WT B6 or B6 IL21 KO mice. A) Mice were evaluated for pulmonary 
function. B) Lungs of mice were stained for Trichrome and the ratio of collagen 
stain to total stain was measured surrounding the bronchioles. C) Lung sections 
were stained with FITC conjugated anti-mouse Ig and the area of Ig deposition 
was measured. D) Whole spleens sections were stained with Rhodamine 
conjugated PNA and the size of the PNA positive sections was measured. 
Representative data from 3 experiments with n=8 mice per group. * P < 0.05; ** 
P < 0.01; *** P < 0.001. 
 
Figure 5: B cells need IL21R for full maturation and progression of chronic 
GVHD. B10.BR recipients were transplanted with either WT BM or IL21R KO BM 
and WT T cells. A) Mice were evaluated for pulmonary function. B) Lungs of mice 
were stained for Trichrome and the ratio of collagen stain to total stain was 
measured surrounding the bronchioles. C) Lung sections were stained with FITC 
conjugated anti-mouse Ig and the area of Ig deposition was measured. D) Whole 
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spleens sections were stained with Rhodamine conjugated PNA and the size of 
the PNA positive sections was measured. Representative data from 3 
experiments with n=8 mice per group. * P < 0.05; ** P < 0.01; *** P < 0.001. 
 
Figure 6: ICOS or CD40L costimulatory pathway blockade is sufficient for 
reducing GCs and preventing BOS. chronic GVHD was established in B10.BR 
mice transplanted with WT B6 BM and WT B6 T cells and mice were treated with 
either anti-ICOS, anti-CD40L or irrelevant rat antibody from D28-56. A) 
Pulmonary function test. GC size was analyzed in situ by measuring the PNA 
positive sections in transplanted spleens from D56. Splenocytes were harvested 
from transplanted mice on D56 and made into single-cell suspension and 
analyzed for C) Tfh or D) GC B cells. E) Amount of Ig deposited in the lungs of 
transplanted mice on D56 with F) representative images. G) Quantified 
Trichrome present in the lungs of mice on D56 with H) representative images. 
Representative data from 2 experiments with n=8. * P < 0.05; ** P < 0.01; *** P < 
0.001. 
 
Figure 7: Anti-IL21 mAb reverses BOS. chronic GVHD was established in 
B10.BR mice transplanted with WT B6 BM and WT B6 T cells and mice were 
treated with either irrelevant mouse IgG1 or anti-IL21. A) PFTs from mice treated 
with either neutralizing anti-IL21 mAb or irrelevant mAb. Splenocytes were 
isolated and analyzed for B) GC B cells or C) Tfh cells. D) Ig and E) ratio of 
trichrome positive to total area surrounding bronchioles in Trichrome stain.  
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Representative data from 3 experiments with n=8. * P < 0.05; ** P < 0.01; *** P < 
0.001. 
 
Supplemental Figure 1: Pathogenic antibody deposition in lungs of anti-
CD20 treated mice. Lungs from day 60 B10.BR mice transplanted with WT B6 
Bone Marrow and splenic T cells were stained for specific IgG subtype: either 
irrelevant/anti-CD20 antibody (IgG1) or pathogenic antibody (IgG2c). 
 
Supplemental Figure 2: ICOS deficiency in donor derived T cells is 
necessary for development of pathogenic pulmonary function. Day 60 
pulmonary function tests for mice transplanted with BM and splenic T cells from 
WT or ICOS deficient B6. 
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Chapter IV: Targeting of Syk in B-cells during murine and human  
chronic graft-versus-host disease  
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Novel therapies for chronic graft-versus-host disease (cGVHD) are needed. 
Aberrant B cell activation has demonstrated in mice and humans with cGVHD.  
Having previously found that human cGVHD B cells are activated and primed for 
survival, we sought to further evaluate the role of the spleen tyrosine kinase 
(Syk) pathway in cGVHD. In murine models, we found that Syk expression was 
necessary in donor B but not T cells for disease progression in a model of 
antibody- and germinal center (GC) B cell dependent cGVHD. In cGVHD mice, a 
small molecule inhibitor of Syk, Fostamatinib, was effective in treating disease 
and normalizing GC formation. We further demonstrated that Syk inhibition was 
effective at inducing apoptosis of human cGVHD B cells. Together these data 
demonstrate the therapeutic potential of targeting B-cell Syk signaling in cGVHD.  
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Introduction 
The development of cGVHD is a major complication following allogeneic 
hematopoietic stem cell transplantation. Discovery of new therapies has been 
limited by the absence on murine models that closely represent the clinical 
human disease and pathogenesis65, 88. Herein we use a mouse model of 
antibody-dependent, multi-organ system cGVHD, previously demonstrated to 
mimic several aspects of human cGVHD pathology24, 89 to validate a novel 
therapeutic for cGVHD.  
While the exact mechanisms of cGVHD remain unknown, recent studies 
have elucidated a role for antibody production by B-cells. The increase of B-cells 
in the germinal center (GC) has been shown to be necessary for the 
development of cGVHD89. Spleen tyrosine kinase (Syk) is activated by B-cell 
receptor (BCR engagement. After antigen-BCR engagement, Syk is 
phosphorylated at Y348, allowing for B-cell survival and proliferation. Increased 
proximal BCR signaling was recently described in cGVHD patient B cells.90 
We sought to determine whether B-cell Syk activation was a critical 
component in cGVHD pathophysiology. First, we demonstrated that Syk was 
hyperactive in B-cells during cGVHD and that Syk expression was necessary in 
B- but not T-cells for murine cGVHD progression. Next, we demonstrated that in 
vivo molecular inhibition of Syk with Fostamatinib was sufficient for decreasing 
murine cGVHD manifestations and inducing apoptosis in human cGVHD B cells. 
These data together suggest that Syk targeting could be a novel therapeutic for 
cGVHD patients. 
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Results/Discussion  
Syk activation and expression are necessary for the development of murine 
cGVHD  
 To determine if Syk is hyper-activated during murine cGVHD, purified B 
cells from day 60 cGVHD spleens were assayed for Syk phosphorylation. There 
was an increase in the percentage pSyk in both BCR stimulated B-cells (Figure 
1A) and unstimulated B-cells in cGVHD (Supplemental Figure 1). These data 
extend a recent report that human B-cells have increased pSyk during cGVHD81, 
potentially ascribed to increased soluble B-cell activating factor (BAFF)19. 
To test whether Syk is necessary for cGVHD progression, mice were 
transplanted with WT or conditional Syk KO BM and WT T-cells and analyzed for 
disease on day 60. Mice receiving Syk KO BM did not develop cGVHD 
pulmonary dysfunction compared to those receiving WT BM and T-cells (Figure 
1B). In contrast, addition of Syk KO donor T-cells did not attenuate lung 
pathology compared to Syk-proficient WT T cell transplanted mice (Supplemental 
Figure 2). While T cell effects after Syk inhibition were previously described in 
acute9 and sclerodermatous cGVHD92, in this model donor T-cell Syk was not 
required for cGVHD development.  
Since Syk is necessary for the proliferation of B-cells following antigen 
stimulation93, we analyzed the spleens of transplanted mice to determine if there 
was a defect in the maintenance of Syk KO BM-derived B-cells. We found that B-
cell frequency in mice receiving Syk KO BM was decreased 8-fold (Figure 1C), 
while T cell frequency was unaffected. These data are consistent with the 
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dependency of activated B-cells on Syk for proliferation and survival, and a 
requirement for activated donor-derived BM B-cells in cGVHD pathogenesis24, 89.  
 
Pharmacological inhibition of Syk decreases murine cGVHD and induces 
apoptosis in human cGVHD B-cells 
Fostamatinib is a potent small molecule inhibitor of Syk. Studies in 
rheumatoid arthritis have demonstrated efficacy with Fostamatinib in randomized 
phase II clinical trials.94, 95 Fostamatinib was notably safe in patients treated for 
non-Hodgkin’s lymphoma, including some who had received prior autologous 
HCT.96. Additionally, Leonhardt et. al.91 demonstrated that Syk inhibition 
decreased costimulatory molecules on antigen-presenting cells and increase 
survival of mice during acute GVHD while preserving anti-tumor and anti-viral 
immunity. To determine the effect of Fostamatinib on murine cGVHD, treatment 
was initiated on d28, a time of active disease.24, 89 Mice receiving Fostamatinib 
had restoration of pulmonary function, similar to the healthy transplanted controls 
(Figure 2A). Improvement in pulmonary function correlated with a reduction in 
cGVHD pathology in the lung (Figure 2B). The number of GC reactions in the 
spleen was decreased in Fostamatinib versus vehicle treated cGVHD mice 
(Figure 2C). This is highlighted by a decrease in frequency of splenic GC B-cells 
in Fostamatinib treated cGVHD mice, matching healthy transplanted mice 
controls (Figure 2D).  
To determine if human cGVHD B cells are more susceptible to Syk 
inhibition, B-cells purified from human peripheral blood were treated in vitro with 
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R406, the active form of R788. There was increased apoptosis in B cells in 
patients with cGVHD compared to healthy patients (Figure 2E and Supplemental 
Figure 3). These data, consistent with work by Allen et. al,81  reveal that R406 
preferentially kills cGVHD B cells via apoptosis. Global targeting of B cells with 
rituximab has been met with mixed success possibly due to altered B cell 
homeostasis perpetuated in some patients.20, 97 We now demonstrate that 
constitutively activated B cells can be selectively targeted in cGVHD.  
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Materials and Methods 
Mice 
C57Bl/6 (B6; H2b) mice were purchased from the National Cancer Institute. 
B10.BR (H2k) mice were purchased from Jackson Laboratories. The Syk fl/fl x 
ERT2-cre mice were provided by RAC from Columbia University. Deletion of Syk 
occurred with daily administration of 1mg tamoxifen PO per mouse for 5 days 
(Sigma) and confirmed by Western Blot. Mice were housed in a specific 
pathogen-free facility and used with the approval of the UMN institutional animal 
care. 
 
BMT 
B10.BR recipients were conditioned with 120 mg/Kg cyclophosphamide and total 
body irradiation (8.3 Gy)89.  Recipients received 10x106 T cell depleted bone 
marrow (BM) cells from B6 wildtype (WT) or conditional Syk knockout (KO) BM 
cells with or without purified splenic T-cells (0.1x106) from WT vs KO donors. 
Where indicated, cGVHD recipients were given R788 (30 mg/Kg/animal/twice 
daily) or 0.4% methylcellulose vehicle from d28-56. Both pro-drug, R788, and its 
active metabolite, R406 (both known as Fostamatinib) were kindly provided by 
Rigel Pharmaceuticals. Lung function was assessed as previously described.89 
 
Patient Samples 
Samples were obtained from patients following written informed consent in 
accordance with the Declaration of Helsinki. The Institutional Review Boards at 
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the University of North Carolina Chapel Hill, Duke University Medical Center, and 
the Dana-Farber Cancer Institute approved all studies. 
 
Flow Cytometry 
B-cells were purified from murine cGVHD by magnetic separation with (Stem Cell 
Technologies) spleens on d60 and activated by 5 µg/mL anti-IgM Fab (Jackson 
Research), fixed and permeabilized and stained with anti-Syk Y348 PE 
(eBioscience). GC B cells were labeled with anti-CD19, anti-GL7 (eBioscience) 
and anti-CD95 (BD Biosciences) and analyzed on BD LSRFortessa. Ficoll 
purified human PBMC were stimulated and stained for Annexin V as previously 
described.90, 98 
 
Frozen tissue preparation, pathology and immunofluorescence Organs 
harvested were embedded in Optimal Cutting Temperature compound, snap 
frozen, and stored at -80°. GC detection and pathologic scoring were 
accomplished as previously described89. 
 
Statistics  
Group comparisons of pathology, pulmonary function tests, cell counts and flow 
cytometry data were analyzed by Student t-test.  
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Figure Legends 
Figure 1: Syk activation during chronic GVHD is necessary during chronic 
GVHD in a murine model. A) Splenocytes from B10.BR mice transplanted with 
B6 BM and low numbers of T cells were analyzed for phosphorylated SYK at 
Y348 after ex vivo stimulation by 5 µg/mL of anti-IgM. B) Day 60 Pulmonary 
function tests of mice transplanted with conditional Syk deficient BM and WT T 
cells. C) Frequency of B cells in transplanted mice on day 60 after transplant. * p 
< 0.5; ** p < 0.01; *** p < 0.001. 
 
Figure 2: Inhibition of Syk by R788 is capable of decreasing B cells in 
murine and human chronic GVHD. A) Pulmonary function tests on mice treated 
with 30 mg/Kg of R788 on day 56. B) GVHD pathology scores from the lungs of 
mice on Day 60. C) Number of germinal centers present in situ in spleens of 
mice. D) Frequency of germinal center B cells (gated on CD19+ GL7+ CD95hi) 
present in the spleens of transplanted mice on day 60. E) Peripheral blood 
mononuclear cells from patients without chronic GVHD (n = 3, open circles) and 
with chronic GVHD (n = 3, filled squares) treated with R406 (0, 0.01, and 0.1 µM) 
as indicated for 48 h. Apoptotic B cells were defined as CD19+ Annexin V+ 
7AAD- cells. Fold increase in apoptosis by R406 divided by PBS is depicted. 
Data are mean +/- range pooled from 3 independent experiments. * p < 0.5; ** p 
< 0.01; *** p < 0.001. 
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Supplemental Figure 1. Phosphorylated Syk in purified B cells during 
chronic GVHD. B cells were purified from the spleens of healthy control (BM 
Only) or chronic GVHD (BM + T) mice and stimulated with anti-IgM at 5 µg/mL 
for 5 minutes. 
 
Supplemental Figure 2. Syk in T cells has no effect on chronic GVHD 
progression. Pulmonary function tests from mice transplanted with WT BM and 
wither WT T cells of Syk deficient T cells. * p < 0.5; ** p < 0.01 
 
Supplemental Figure 3. Increased apoptosis in human chronic GVHD B 
cells when treated with increasing concentrations of R406. Representative 
flow plots of purified B cells from human PBMC with or without chronic GVHD.  
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Chapter V: Ibrutinib Treatment Ameliorates Murine Chronic Graft-versus-
Host Disease 
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Chronic graft-versus-host disease (cGVHD) is a life-threatening impediment to 
allogeneic hematopoietic stem cell transplantation that is mediated by CD4+ T-
cells and B-cells. Current therapies are incompletely effective in preventing and 
treating cGVHD. Ibrutinib is an FDA-approved irreversible inhibitor of Bruton’s 
tyrosine kinase (BTK) and IL-2 inducible T-cell kinase (ITK) that targets Th2 cells 
and B-cells and produces durable remissions in B-cell malignancies with minimal 
toxicity. To determine whether ibrutinib could reverse established cGVHD, we 
utilized two complementary murine models focused on interrogating T-cell driven 
sclerodermatous cGVHD (minor antigen disparate, LP/J→C57BL/6) or 
alloantibody driven multi-organ system cGVHD including bronchiolar obliterans 
(BO) (MHC disparate, C57BL/6→B10.BR). In the LPJ→C57BL/6 model, ibrutinib 
treatment delayed cGVHD progression, improved survival, and ameliorated 
cGVHD clinical and pathological manifestations. In the C57BL/6→B10.BR model, 
ibrutinib treatment restored pulmonary function, reduced germinal center 
reactions, and tissue immunoglobulin deposition. Genetic ablation studies 
confirmed that BTK and ITK were each critical to the development of cGVHD and 
further ex vivo human studies validate our findings in cells derived from patients 
with active cGVHD. Our data demonstrate that cGVHD is driven by B and T-cells 
and that ibrutinib is a potent and promising therapeutic agent that warrants 
consideration for cGVHD clinical trials. 
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Introduction 
Chronic graft-versus-host disease (cGVHD) is a primary cause of non-
relapse mortality after allogeneic hematopoietic stem cell transplantation 
(HSCT)27, 99-101. Drug therapy for cGVHD has been predominantly limited to 
calcineurin inhibitors and steroids, which are incompletely effective and 
associated with infections as well as long-term risks of toxicity102. Novel 
therapeutics that pinpoint pathogenic immune subsets might control cGVHD yet 
preserve immune effector function. 
In contrast to acute GVHD, cGVHD is a relatively acellular process that 
has fibrosis as a dominant feature. The specific immune phenomena that 
underlie cGVHD are variable; however, recent studies show that B-cells, in 
addition to specific CD4 T-cell subsets, are key mediators of cGVHD24, 103, 104. It 
has been demonstrated that pathogenic antibody deposition occurs in human 
cGVHD19, 30-32. A network of alloreactive T-helper cells, including Th1, Th2, Th17, 
and T-follicular helper (Tfh) cells, infiltrate tissues and produce a milieu of 
effector cytokines resulting in antibody deposition, tissue fibrosis, and 
autoimmunity105-107. 
Many of the cellular activation and effector functions of these lymphoid 
subsets can be molecularly tethered to Bruton’s tyrosine kinase (BTK) and IL-2 
inducible kinase (ITK)108, 109. BTK and ITK are highly conserved TEC family 
kinases that propagate immune receptor-based signaling in B and T-
lymphocytes, respectively108. These molecules are activated upstream by SRC 
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family kinases and, upon autophosphorylation, drive downstream activation of 
NF-κB, MAPK, and NFAT in lymphocytes, resulting in cellular activation, release 
of soluble effector molecules, and rapid proliferation110. Antibody production by 
B-cells hinges upon the function of BTK109. Whereas Th1, T-regulatory (Treg), 
and CD8 effector T-cells have both ITK and resting lymphocyte kinase (RLK, aka 
TXK) to drive activation, epigenetic evolution of Th2 and Th17 cells conserves a 
singular dominant role for ITK109, 111-115. This TEC- kinase profile difference 
provides an avenue to selectively target T-cell subsets that potentially are highly 
relevant to cGVHD. However, to date the individual impact of BTK or ITK on the 
development of cGVHD is unknown. 
Ibrutinib is a first-in-class irreversible inhibitor of BTK and ITK that blocks 
downstream immune receptor activation116-118. Numerous in vitro and in vivo 
studies confirm the specific activity and clinical safety of ibrutinib for the 
treatment of specific TEC-kinase dependent malignancies119-122. Since ibrutinib 
can block the activation of B-cells via BTK inhibition as well as specific T-helper 
subsets that drive the development of cGVHD via ITK inhibition, we hypothesize 
that it may be ideally suited to the treatment of cGVHD. 
To study the multifaceted effects of this inhibitor in vivo and interrogate the 
activity of both T and B-cells in the development of multi-organ systemic cGVHD, 
we used two complementary murine allogeneic HSCT models representing 
sclerodermatous and non-sclerodermatous cGVHD manifestations. Here, we 
show that ibrutinib treatment ameliorates the progression of cGVHD in the 
LP/J→C57BL/6 T-cell dependent murine model of sclerodermatous cGVHD, 
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reducing skin lesions, hair loss, and lymphohistiocytic infiltration123. Therapeutic 
administration of ibrutinib also proved effective at combating cGVHD in the 
C57BL/6→B10.BR model, which develops bronchiolitis obliterans syndrome (BO) 
and multi-organ cGVHD without skin involvement36. In this model, ibrutinib 
blocked germinal center (GC) formation and immunoglobulin (Ig) deposition, 
reduced tissue fibrosis, and reversed BO-associated pulmonary dysfunction. 
Genetic studies confirmed that ITK and BTK are independently critical for the 
development of cGVHD. These data strongly support the clinical investigation of 
ibrutinib as a novel therapeutic strategy for the treatment of cGVHD. 
Results 
Therapeutic administration of ibrutinib limits of the development of 
sclerodermatous lesions in a T-cell driven murine cGVHD model. To assess 
the efficacy of ibrutinib as a therapeutic intervention for cGVHD, we used the 
LP/J→C57BL/6 model of sclerodermatous cGVHD which develops dermal 
lesions characterized by hair loss, redness, flaking, scabbing, hunched posture, 
and thickened skin123. In this murine model, symptoms become apparent 
between days 20 and 25 and peak between days 37 and 47 after hematopoietic 
stem cell transplant (HSCT). Ibrutinib or vehicle treatment was initiated in 
randomized cohorts at day 25, after the initial signs of cGVHD (weight loss, hair 
loss, skin redness/flaking, hunched posture, or immobility) were visible in the 
majority (72%) of mice. Upon inspection at day 39 (14 days after starting 
therapy), ibrutinib-treated mice clearly lacked the sclerodermatous lesions, hair 
loss, hunched posture, and scabbing that were observed in both the vehicle and 
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cyclosporine treatment groups (Figure 1A). The development of cGVHD in this 
model was not effectively constrained by 10mg/kg/day cyclosporine 
(Supplementary Figure 1). Histology of representative skin lesions obtained at 
day 60 from vehicle- or cyclosporine-treated mice confirmed dermal fibrosis, 
epidermal hyperplasia, serocellular crusting, erosion, and lymphohistiocytic 
infiltration, which were not observed in skin samples from the ibrutinib-treated 
group (Figure 1B-C and Supplementary Figure 2-3). 
Ibrutinib improves cGVHD progression-free survival and diminishes 
cGVHD. 
To define cGVHD severity and progression in the LP/J→C57BL/6 model, we 
used a scoring system that quantitatively grades cGVHD metrics including: 
bodyweight, posture, mobility, hair loss, skin lesions, and vitality on a scale from 
0 to 19 by a consistent and trained unbiased observer in a coded (blinded) 
manner124. Overall, 72% of mice (34 of 47) had active cGVHD on day 25 and the 
randomly assigned cohorts were very similar in initial (day 25) cGVHD score 
(ibrutinib = 1.5, vehicle =1, cyclosporine = 2.9). Using these metrics we found 
that mice treated with ibrutinib significantly reduced the overall intensity of 
cGVHD compared with vehicle treatment (p=0.0184) (Figure 2A and 
Supplementary Figure 4). Chronic GVHD progression in this model is defined as 
a >2 point increase in cGVHD score from the initiation of therapy. Data derived 
from two independent experiments show that ibrutinib significantly extended 
median time to cGVHD progression by 14 days; 33% (6 of 18) of ibrutinib treated 
mice remained progression-free as compared to 12% (2 of 18) of mice receiving 
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vehicle (p<0.02) (Figure 2B, and Supplementary Figure 5). During the study 
period, we observed 100% survival in the ibrutinib cohort compared with 82% 
and 88% survival for cyclosporine and vehicle groups, respectively 
(Supplementary Figure 6). Weekly evaluation of mouse body weights revealed 
little variation between groups (Supplementary Figure 7). To understand the 
sustained therapeutic benefits of ibrutinib and the potential for drug withdrawal 
we conducted an additional long-term therapeutic experiment (Figure 2C). Once 
again, in this separate experiment, ibrutinib significantly limited cGVHD 
progression as compared to vehicle control (p=0.0019). We also found that 
withdrawal of therapy at day 60 permitted breakthrough cGVHD in a single 
mouse (1 of 6); however this was not statistically significant. Analysis of internal 
cGVHD pathology within the pulmonary and renal tissues on day 75 suggested 
that continuous long-term ibrutinib was a more effective at controlling cGVHD 
(Supplementary Figures 8-9). Prophylactic ibrutinib treatment initiated pre-HSCT 
at day -2 and concluded at day 25 did not yield a significant improvement in 
cGVHD progression (Supplementary Figure 10). 
Ibrutinib controls cGVHD-induced organ injury. 
In addition to the externally measurable cGVHD metrics, we demonstrated that 
the LP/J→C57BL/6 model consistently develops pulmonary and renal cGVHD 
whereas other cGVHD pathologies are infrequently observed. Evaluation of H&E 
stained sections revealed that, compared with vehicle controls, ibrutinib therapy 
reduced cGVHD-related aggregation of lymphocytes, plasma cells, and 
histiocytes surrounding bronchioles and small caliber vessels throughout the 
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pulmonary parenchyma and within the renal interstitium. Immunohistochemistry 
revealed B220+ B-cell and CD3+ T-cell pulmonary infiltration in addition to CD3+ 
T-cell renal infiltration in both the vehicle and cyclosporine groups, which was not 
observed in ibrutinib treatment groups (Figure 3A and Supplementary Figure 11). 
Coded pathologic analysis confirmed that ibrutinib improved systemic cGVHD in 
this model (p=0.0099 for lung and p=0.0124 for kidney) (Figures 3B-C and 
Supplementary Figures 11).  
Therapeutic administration of ibrutinib ameliorates pulmonary fibrosis and 
the development of bronchiolitis obliterans. 
Chronic GVHD is characterized by a wide variety of autoimmune phenomena 
that are incompletely recapitulated by any single in vivo animal model. Recently 
published consensus criterion from the National Institutes of Health considers BO 
the only pathognomonic manifestation of cGVHD within the lung17. The 
C57BL/6→B10.BR model develops multi-organ system disease including BO 
starting at day 28 post-HSCT. Therapeutic administration of ibrutinib beginning at 
day 28 and continuing indefinitely curtailed the development of BO in vivo as 
measured by pulmonary resistance (p=0.0090), elastance (p=0.0019), and 
compliance (p=0.0071) (Figures 4A, B, and C). Masson trichrome staining of 
inflated pulmonary tissues from 4 mice derived from 3 experiments revealed less 
peribroncheolar collagen fibrosis among ibrutinib-treated animals (Figure 4D) and 
a significant reduction in pulmonary fibrosis (p<0.0001) (Figure 4E). We observed 
100% survival in the ibrutinib cohort, versus 95% in the vehicle and 82% in the 
cyclosporine groups (Supplementary Figure 12). Weekly evaluation of mouse 
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body weight revealed little variation between groups. To examine the sustained 
benefit of ibrutinib therapy in this model we conducted a separate set of 
experiments where mice were withdrawn from ibrutinib on day 56 post transplant. 
Pulmonary function tests at day 60 and day 90 reveal that short-term ibrutinib 
therapy causes an eventual loss of benefit, supporting the need for continued 
therapy (Supplementary Figure 16). Day -2 to day 28 prophylactic administration 
of ibrutinib in this model also did not effectively combat cGVHD or BO (data not 
shown). Overall, these data indicate that ibrutinib therapy reduces the underlying 
fibrotic pathogenesis of BO in the C57BL/6→B10.BR cGVHD model. 
Ibrutinib limits in vivo germinal center reactions and Ig deposition in 
pulmonary tissues. 
Ibrutinib’s ability to block BCR-induced activation of BTK is well defined; 
however, it remains unclear if GC reactions are effectively inhibited. To study 
this, we utilized the C57BL/6→B10.BR mouse model in which robust GC 
reactions sustain pathogenic B- lymphocytes and lead to Ig deposition within the 
liver and lungs and the development of BO. Peanut agglutinin staining revealed 
GC reactions within the spleen, and ibrutinib therapy reduced the overall size, 
cellularity, and number of GC reactions compared with vehicle treated mice with 
active cGVHD (p<0.001)(Figure 5A-B). On day 60 after HSCT, isolated 
splenocytes from chimeras were analyzed by flow cytometry for 
CD19+/GL7+/CD38lo germinal center B-cells. Ibrutinib significantly inhibited the 
cGVHD-induced formation of germinal centers within the spleen (p=0.0222) to 
numbers comparable to the no cGVHD, BM only control (Figure 5C). 
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The functional product of alloreactive GC B-cells is secreted Ig, which deposits 
within healthy tissues. In the C57BL/6→B10.BR cGVHD model, BO is 
inextricably related to the deposition of soluble Ig within pulmonary tissues and 
the fibrotic cascade that this initiates. By blocking B-cell reactivity, ibrutinib limited 
pulmonary deposition of Ig as quantified at day 60 post-HSCT using 
immunofluorescent microscopy (Figure 5D). Quantification of the 
immunofluorescent signal revealed elimination of pulmonary Ig deposition after 
therapeutic ibrutinib treatment (p<0.001) (Figure 5E). Together, these data 
confirm that a clinically relevant downstream effect of ibrutinib therapy in the 
setting of cGVHD is the blockade of Ig deposition within healthy tissues. 
Genetic ablation of BTK or ITK activity in allogeneic donor cell engraftment 
confirms that both TEC kinases are required for the development of 
cGVHD. 
The XID mouse in which the kinase activity of BTK is genetically abrogated and 
the Itk- /- mouse have been fully characterized on the C57BL/6 genetic 
background125, 126. Given ibrutinib’s ability to inhibit both ITK and BTK, we sought 
to examine the relative independent contributions of ITK and BTK to the 
development of cGVHD. We therefore examined pulmonary function at day 60 
after HSCT, as this represents a primary functional measurement of cGVHD-
induced lung injury and fibrosis in the C57BL/6→B10.BR model. 
Chronic GVHD sustaining T-cells in this model originate from mature 
lymphocytes in the donor cell graft. To recapitulate the effect of ITK inhibition 
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within these cGVHD causative T-lymphocytes, we administered Itk-/- splenic T-
cells along with BM from wild- type mice to allogeneic recipients. Day 60 
pulmonary function tests including resistance, elastance, and compliance were 
uniformly and significantly (p=0.0014; p=0.0028; p=0.0003) reduced in mice 
receiving Itk-/- vs. wild-type splenic T-cells and comparable to non-cGVHD, BM 
only controls. These data reveal that T-cell ITK activity is necessary for the 
development of cGVHD. 
Data from both cGVHD models implicates hyper-reactive BTK. To genetically 
confirm the role of BTK signaling in cGVHD, we infused XID BM along with wild-
type splenic T-cells to mimic BTK inhibition. Pulmonary function tests conducted 
at day 60 after HSCT revealed that BTK activity was essential to the 
development of BO (Figure 7). Pulmonary resistance, elastance, and compliance 
were significantly reduced in recipients of wild-type T cells and XID versus wild-
type BM (p=0.0025; p=0.0025; p=00.496) and comparable to XID or wild- type 
BM only controls. 
Ibrutinib blocks T and B-cell activation in samples obtained from patients 
with active cGVHD. 
Our data confirm that BTK and ITK are critical to the development of cGVHD and 
that ibrutinib works to alleviate the symptoms associated with severe cGVHD in 
murine models. To confirm that this effect is not restricted to mouse models we 
tested the effects of ibrutinib on CD4-T and B-cells obtained from patients with 
active and persistent cGVHD. Data revealed that after pretreatment with 1µM 
	   115	  
ibrutinib CD4 T-cells from these patients demonstrated lower surface expression 
of CD69 after ex vivo T-cell receptor (TCR) stimulation using anti-CD3 (p=0.033) 
(Figure 8A). Moreover, purified B- cells that were pretreated with 1µM ibrutinib 
showed lower levels of pBTK-Y223, pPLCγ2-Y1217, and pERK1/2 by 
immunoblot analysis (Figure 8B). These data confirm that ibrutinib can curtail 
immune receptor activation of human B and T-cells in the setting of active 
cGVHD. 
Discussion 
Chronic GVHD develops from coordinated effects of both B and T-cells, and 
multiple key functions of these cells are driven by TEC family kinases. Here, we 
show that that neither XID BM nor Itk-/- donor T-cells facilitate the development 
of systemic cGVHD in mice, identifying the importance of the TEC kinases BTK 
and ITK in cGVHD and identifying these two enzymes as therapeutic targets in 
this disease. Therefore, because of its ability to simultaneously target BTK and 
ITK, ibrutinib holds specific promise for the treatment of cGVHD. Our studies 
utilize two distinct but complementary, validated murine models of cGVHD; one 
that has dominant sclerodermatous features, and the other with a non-
sclerodermatous, multi-organ system fibrotic disease with BO36, 123. Our results 
indicate that ibrutinib targets B and T-cell driven GC responses and is remarkably 
effective in treating cGVHD. In the sclerodermatous model, animals receiving 
therapeutic ibrutinib were often indistinguishable from their healthy counterparts, 
and in the non-sclerodermatous cGVHD model, no cGVHD manifestations were 
evident even at the end of the observation period. Moreover, GC reaction size, 
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cellularity, and number were lower in mice receiving ibrutinib, correlating to a 
partial but significant resolution of cGVHD symptoms. These data are consistent 
with preclinical data in which GC reactions are key to cGVHD pathogenesis; for 
instance, clinical responses to rituximab (anti-CD20 mAb) have been observed, 
implicating B cells as etiopathogenic in human cGVHD45, 127. Finally, we 
confirmed that our observation could be applied to human therapy by testing 
ibrutinib’s capacity to block the molecular activation of T-cells and B-cells directly 
obtained from patients with active ongoing cGVHD. 
our genetic ablation models reveal that BM-derived B cells are dependant upon 
BTK for GC formation. Similarly, Itk-/- splenocytes are unable to cause cGVHD, 
suggesting that ITK is critical for T-cell support of the fibrotic cascade. While XID 
and Itk-/- mice are useful in exploring the mechanisms responsible for cGVHD 
generation, there are caveats. For instance, TEC kinase can compensate for the 
lack of BTK in the XID mouse model, and complete genetic ablation of ITK blunts 
thymic maturation of functionally mature T-lymphocytes128, 129. As a result, we 
can conclude that ITK and BTK are necessary components for the development 
of cGVHD; however we cannot conclude that ibrutinib’s therapeutic efficacy is 
solely driven by inhibition of these two TEC kinases. 
In the cGVHD model that has BO as an important feature, fibrosis occurs by day 
28 post-HSCT. Intriguingly, ibrutinib treatment beginning day 28 after HSCT in 
mice with established cGVHD resulted in resolution of fibrosis, suggesting that 
treatment in the early phase of cGVHD can permit tissue repair and further 
suggesting that ongoing antibody deposition in cGVHD target organs may be 
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required for a persistent fibrogenic process. Notably, for patients with debilitating 
cGVHD from fibrosis, therapies include supportive care, high dose steroids, 
rapamycin, mycophenolate, imatinib, extra-corporal photopheresis, IL-2 and lung 
transplant, all with incomplete efficacy and potentially serious complications130, 
131. Although conclusions from rodent cGVHD must be validated in patients, our 
studies collectively indicate that a wide spectrum of cGVHD patients may benefit 
from ibrutinib therapy. 
To examine the importance of sustained therapy we conducted studies using 
both cGVHD models in which mice were withdrawn from ibrutinib therapy around 
day 60 post HSCT. In general, we observed a loss of efficacy with removal of the 
drug, however not all metrics were statistically significant. These data are 
consistent with our molecular understanding which would imply that pathogenic 
T-cells and B-cells are restrained by the inhibitor but not actively depleted. 
Overall, these data would direct caution in the clinical setting when attempting to 
taper such an inhibitor. 
To study prophylactic efficacy, we initiated ibrutinib treatment two days prior to 
HSCT and continued until we begin to observe cGVHD (approximately 28 days). 
Although post-transplant administration of ibrutinib effectively controlled cGVHD, 
we found that prophylactic treatment was ineffective under these conditions. The 
ideal time frame for ibrutinib administration may coincide with the establishment 
of robust T-cell driven GC reactions that may take up to 1 month; prophylactic 
treatment alone may be ineffective for this reason. Furthermore, unlike rituximab, 
ibrutinib does not directly kill B-cells; instead it prevents downstream BCR 
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activation, arresting cells in an unstimulated state. This effect can be lost after 
withdrawal of ibrutinib. Together, our data indicate that ibrutinib is likely to be 
better for cGVHD therapy as opposed to prophylaxis, should preclinical studies 
translate into the clinic. 
Our studies focus on ibrutinib’s effect on cGVHD; however the effects on 
infectious complications and leukemic relapse remain unanswered. Recent 
mouse and human studies indicate that ibrutinib improves the immune 
competence with regard to infectious complications, however this has yet to be 
tested in the HSCT setting118, 121. Ibrutinib also has direct anti-leukemic effects in 
both B-cell derived tumors and AML supporting the notion that it may directly aid 
in relapse prevention132, 133. 
Overall, our complementary in vivo models demonstrate a clear therapeutic 
benefit derived from therapeutic administration of ibrutinib to reduce the 
prolonged autoimmune effects of cGVHD. In addition, our ex vivo human data 
suggest that these conclusions likely extend to the setting of human cGVHD. 
These data support the future study of this promising therapeutic agent in 
cGVHD as well as the exploration of novel strategies which target specific TEC 
kinases in the setting of allo-HSCT. 
Methods 
Mice: C57BL/6 (H2b) mice were purchased from the National Cancer Institute or 
from The Jackson Laboratory (Bar Harbor, Maine). LP/J and B10.BR (H2k) mice 
were purchased from The Jackson Laboratory. The C57BL/6 XID mouse, in 
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which a specific mutation abrogates BTK kinase activity, was obtained from The 
Jackson Laboratory. The C57BL/6 Itk-/- mouse was a kind gift from Dr. Leslie 
Berg (University of Massachusetts)(58). Both strains are maintained on the 
defined C57BL/6 genetic background. All mice were housed in a pathogen-free 
facility at The Ohio State University or The University of Minnesota and used with 
the protocol approval of the respective institutional animal care committees. 
Therapeutic HSCT models: The C57BL/6→B10.BR model has been described 
previously(7). In brief, B10.BR recipients conditioned with 120mg/kg/day I.P. 
cyclophosphamide (Cy) on days -3 and -2 and 8.3 Gy TBI (using a 137 Cesium 
irradiator) on day -1 were engrafted with 1X107 Thy1.2 depleted C57BL/6 derived 
bone marrow (BM) cells with (or without) 1X106 allogeneic splenocytes. 
Experiments with the LP/J→C57BL/6 model were conducted using similar 
methods to those previously described. Briefly, C57BL/6 recipients were 
conditioned with 8.5Gy X-ray TBI on day 0 and were provided 1X107 LP/J-
derived bone marrow (BM) cells and 2X106 splenocytes by tail-vein injection. 
Mice surviving to day 25 begin to show clinical and pathologic changes 
consistent with systemic cGVHD frequently involving the skin, lung, and kidneys, 
and infrequently involving hepatic or salivary gland lymphohistiocytic infiltration, 
conjunctivitis, anterior uveitis, esophagitis and corneal ulcers. In our hands, this 
specific splenocyte and irradiation dose produces a cGVHD phenotype, devoid of 
the classic gastrointestinal lesions, splenic atrophy, or diarrhea associated with 
aGVHD. The development of cGVHD was measured in coded fashion using a 
modified version of the scoring system originally described by Cooke et al. 
	   120	  
(Supplementary Table 1).Therapeutic administration of ibrutinib (kindly provided 
by Pharmacyclics, Inc.) via drinking water was conducted as previously 
described(27). Mice received a dose of 15 mg/Kg/day ibrutinib in 0.4% 
methylcellulose by intraperitoneal (IP) injection starting day 28 post-transplant for 
the C57BL/6→B10.BR model or 25 mg/kg/day via drinking water starting at day 
25 post-transplant for the LP/J→C57BL/6 model. Drinking water administration 
daily dose was calculated previously. In the latter strain combination, a cohort of 
mice was given cyclosporine A administered IP in 0.2% CMC at 10 mg/kg/day 
starting at day 25 for 2 weeks followed by thrice weekly as previously described. 
Unless otherwise stated, ibrutinib was administered until the end of the study. For 
both cGVHD models the BTK pathway was found to be constitutively activated, 
similar to what has been identified in human cGVHD, and ex-vivo ibrutinib 
treatment yielded attenuation of this signaling pathway (Supplementary Figure 
11).  
Pulmonary function tests: Pulmonary function tests (PFTs) were performed on 
anesthetized mice using whole-body plethysmography with the Flexivent system 
(SCIREQ) as previously described. 
Germinal Center (GC) detection: GC detection was conducted using 6 µm 
spleen cryosections stained using rhodamine peanut agglutinin as previously 
described. 
Masson trichrome staining: Cryosections (6 µM) were fixed for 5 minutes in 
acetone and stained with hematoxylin and eosin and with the Masson trichrome 
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staining kit (Sigma, St. Louis MO) for detection of collagen deposition. Collagen 
deposition was quantified on trichrome stained sections as a ratio of area of blue 
staining to area of total staining using the Adobe Photoshop CS3 analysis tool. 
Histopathological scoring: Coded pathologic analysis of H&E stained sections 
was performed by APM or BKH in an unbiased manner with scores ranging from 
0 to 4(60). For pulmonary tissues, scores indicate the number of 
lymphoplasmacytic and histiocytic cellular cuffs infiltrating the surrounding 
airways or vasculature and the number of infiltrating aggregates. For renal H&E 
stained sections, both perivascular lymphoplasmacytic infiltration and intratubular 
protein were quantified. For additional details see supplementary methods. 
Immunoblot analysis: Experiments were conducted using conventional 
methodology previously described. Blotting was conducted using pBTK-Y223, 
BTK, pPLCγ2- Y1217, PLCγ2, pERK1/2, ERK, and GAPDH (Cell Signaling 
Technologies, Danvers, MA) specific antibodies. 
Statistical analysis: A two-tailed Student’s T-test was used for normal data at 
equal variance. Significance was considered for p<0.05. For cGVHD scoring in 
the LP/J→C57BL/6 model, a linear mixed effects model was applied to assess 
the trends in cGVHD scores from days 33 – 52, using the measurement at day 
25 as a covariate to account for differences in the initial measurement between 
treatments. Chronic GVHD progression in the LP/J→C57BL/6 model was 
prospectively defined as a >2 point increase in cGVHD score from the initiation of 
therapy. 
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Figure Legends 
Figure 1: Scleroderma and skin manisfestations of cGVHD are alleviated by 
ibrutinib therapy. At day 25 mice post-HSCT a total of 18 mice (from two 
independent experiments) were randomly assigned to ibrutinib (25mg/kg/day), 18 
to vehicle, or 11 to cyclosporine (10mg/kg/day). Sclerodermatous lesions, hair 
loss, hunched posture, and gaunt appearance are characteristic visual indicators 
of cGVHD in this model. A) Representative visual analysis of 4 randomly 
selected mice at day 39 post-HSCT. B) H&E stained skin preparations of 
sclerodermatous skin lesions showing levels of dermal fibrosis, epidermal 
hyperplasia, serocellular crusting, erosion, and lymphohistiocytic infiltration, 
consistent with cGVHD. C) Pathologic cGVHD involvement of the skin was 
independently assessed on a scale from 0 to 8 for each mouse. Cohort averages 
are displayed, *=p<0.05, error bars = S.E.M. 
Figure 2: Ibrutinib inhibits autoimmune manifestations of cGVHD. A) Weekly 
blinded analysis of cGVHD external metrics including weight, posture, vitality, 
mobility, coat, and skin in all mice from two independent experiments (18 vehicle, 
18 ibrutinib, and 11 cyclosporine) (Supplementary Table 1). All cGVHD scores 
were corrected for individual scores at the beginning of treatment (day 25). Error 
bars = s.e.m. *=p<0.01 B) Kaplan Meier plot of cGVHD progression free survival. 
Data is derived from two independent experiments. Progression is defined a >2 
point increase in day 25 cGVHD score (Supplementary Table 1) *=p<0.01. C) 
Kaplan Meier plot of cGVHD progression free survival in an independent 
experiment aimed to determine sustained benefits from continued ibrutinib 
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therapy. During the course of the experiment ibrutinib was withdrawn on day 60 
from animals in the Ibrutinib Short Course cohort. **=p<0.001. 
Figure 3: Ibrutinib therapy prevents autoimmune injury in a T-cell 
dependent model of cGVHD. A) Representative 20X images from H&E, B220, 
or CD3 stained lung and kidney tissues from mice sacrificed at day 125 post-
HSCT from 6 mice/group. Images were taken by a trained veterinary pathologist 
who was blinded to animal cohorts. B) Blinded pathologic analysis of H&E 
stained lung tissues obtained from cGVHD cohorts (18 vehicle and 18 ibrutinib). 
Lymphohistiocytic infiltration was graded on a 0-4 scale for each animal. C) 
Blinded pathologic analysis of H&E stained kidney tissues obtained from cGVHD 
cohorts. Portal hepatitis and vasculitis was graded on a 0-4 scale for each 
animal. **=p<0.01, *=p<0.05. 
Figure 4: Collagen deposition and pulmonary function are improved in a 
murine model of bronchiolitis obliterans. A-C) PFTs were performed at day 
60 post- transplant on anesthetized animals. Animals (n=4/group) were artificially 
ventilated and A) resistance, B) elastance, and C) compliance were measured as 
parameters of distress in lung function in animals receiving 5x106 splenocytes 
(S) in addition to bone marrow (BM). Error bars = s.e.m. D) and E) Collagen 
deposition within pulmonary tissues was determined with a Masson trichrome 
staining kit; blue indicates collagen deposition. D) Representative images of 
collagen deposition observed in each treatment cohort (n=8) Blue staining 
represents Masson Trichrome stained collagen. E) Quantification of collaged 
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deposition (n=8) as a ratio of blue area to total area of tissue was performed with 
the analysis tool in Photoshop CS3. Representative data from 3 independent 
experiments. 
Figure 5: Germinal center reactions and pulmonary immunoglobulin 
deposition are reduced with administration of ibrutinib. A) Germinal centers 
were imaged by staining 6 um spleen sections with PNA conjugated to 
rhodamine (red) and DAPI (blue). B) Germinal center area (GC/mm2) was 
calculated from PNA stained immunofluorescent images for each animal. The 
average area for each cohort is displayed. Error bars = s.e.m. C) Splenocytes 
were purified from transplanted mice on day 60 and frequency of germinal center 
B cells was quantified. D) 6µm lung sections from day 60 transplanted mice were 
stained with anti-mouse Ig conjugated to FITC (green) and DAPI (blue) and E) 
quantified with Adobe Photoshop CS3. Representative data from 3 independent 
experiments. For all graphs *= p<0.05, **=p<0.001. All measurements were 
conducted on day 60 post HSCT. 
Figure 6: Development of BO is dependent on ITK expression in donor 
mature T cells. A) Day 60 pulmonary function tests Mice transplanted with WT 
bone marrow and low numbers of either WT T-cells or ITK deficient T cells. B) 
Pathologic scores in lung, liver and spleen of day 60 transplanted mice. n= 5 
mice/group in 2 independent experiments. 
Figure 7: Expression of BTK in donor-derived B cells is necessary for the 
development of BO. A) Day 60 pulmonary function tests from mice transplanted 
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with low levels of WT T-cells and either WT or XID (kinase inactive BTK) bone 
marrow. B) Pathology of lung, liver, and spleen of day 60 transplanted mice. n=5 
mice/group from 2 independent experiments. 
Figure 8: Ibrutinib limits activation of T-cells and B-cells from patients with 
active cGVHD. A) Primary CD4+ T-cells were isolated from patients with active 
cGVHD, pretreated with 1µM ibrutinib (or DMSO), and stimulated using anti-CD3 
for 6 hours. Graph shows the mean florescent intensity (MFI) for CD69 amongst 
CD4+ T-cells for each patient. *=p<0.05. B) B-cells isolated from patients with 
cGVHD were pretreated with 1µM ibrutinib and stimulated with anti-IgM for 45 
minutes. Immunoblot analysis of BTK, ERK, and PLCγ2 was conducted. The 
densitometric quantification of activated proteins relative to total proteins is 
provided. Data are representative of three experiments on three separate 
patients. 
Supplementary Figure 1: At day 25 mice post-HSCT a total of 18 mice (from 
two independent experiments) were randomly assigned to ibrutinib 
(25mg/kg/day), 18 to vehicle, or 11 to cyclosporine (10mg/kg/day). 
Sclerodermatous lesions, hair loss, hunched posture, and gaunt appearance are 
characteristic visual indicators of cGVHD in this model. Representative visual 
analysis of 4 randomly selected mice at day 39 post-HSCT. 
Supplementary Figure 2: H&E stained skin preparations of sclerodermatous 
skin lesions showing levels of dermal fibrosis, epidermal hyperplasia, serocellular 
crusting, erosion, and lymphohistiocytic infiltration, consistent with cGVHD. 
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Supplementary Figure 3: cGVHD involvement of the skin was assessed by a 
trained observer in a blinded fashion on a scale from 0 to 8. Cohort averages are 
displayed. 
Supplementary Figure 4: Weekly blinded analysis of cGVHD external metrics 
including weight, posture, vitality, mobility, coat, and skin in all mice from two 
independent experiments (18 vehicle, 18 ibrutinib, and 11 cyclosporine) 
(Supplementary Table 1). All cGVHD scores were corrected for individual scores 
at the beginning of treatment (day 25). Error bars = s.e.m. *=p<0.01 
Supplementary Figure 5: Kaplan Meier plot of cGVHD progression free 
survival. Progression is defined a >2 point increase in day 25 cGVHD score 
(Supplementary Table 1) *=p<0.01 
Supplementary Figure 6: Kaplan Meier plot of overall survival for vehicle, 
ibrutinib, or cyclosporine treatment groups. 
Supplementary Figure 7: Weekly bodyweight measurements for vehicle, 
ibrutinib, and cyclosporine treatment groups. Bodyweight was calculated to the 
nearest 0.1 gram at a similar time each day. Error bars = s.e.m., samples derived 
from two independent experiments. 
Supplementary Figure 8: Blinded pathologic analysis of H&E stained lung 
tissues obtained from cGVHD cohorts derived from the sustained benefit 
experiment on day 75 post HSCT. Lymphohistiocytic infiltration was graded on a 
0-4 scale for each animal. *=p<0.05. 
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Supplementary Figure 9: Blinded pathologic analysis of H&E stained kidney 
tissues obtained from cGVHD cohorts derived from the sustained benefit 
experiment on day 75 post HSCT. Portal hepatitis and vasculitis was graded on a 
0-4 scale for each animal. *=p<0.05, **=p<0.01. 
Supplementary Figure 10: Prophylactic treatment of cGVHD. 2-days prior to 
HSCT mice are randomly assigned to ibrutinib (25mg/kg/day), vehicle, or 
cyclosporine (10mg/kg/day) groups. Weekly blinded analysis of cGVHD external 
metrics including weight, posture, vitality, mobility, coat, and skin (Supplementary 
Table 1). All cGVHD scores were corrected for individual scores at the beginning 
of treatment (day -2). Error bars = s.e.m. 
Supplementary Figure 11: Representative 20X images from H&E, B220, or 
CD3 stained lung and kidney tissues from mice sacrificed at day 125 post-HSCT 
from 6 mice/group. Images were taken by a trained veterinary pathologist who 
was blinded to animal cohorts. Blinded pathologic analysis of H&E stained lung 
tissues obtained from cGVHD cohorts (18 vehicle, 18 ibrutinib, and 11 
cyclosporine). Lymphohistiocytic infiltration was graded on a 0-4 scale for each 
animal. *=p<0.05, **=p<0.01. Blinded pathologic analysis of H&E stained kidney 
tissues obtained from cGVHD cohorts. Portal hepatitis and vasculitis was graded 
on a 0-4 scale for each animal. *=p<0.05. 
Supplementary Figure 12: PFTs were performed at day 60 or day 90 post-
transplant on anesthetized animals to understand sustained benefits. Animals 
were artificially ventilated and resistance, elastance, and compliance were 
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measured as parameters of distress in lung function in animals receiving 5x106 
splenocytes (S) in addition to bone marrow (BM). Treatment cohorts were 
administered vehicle or ibrutinib starting on day 28 and ending on day 56 post 
transplant; Error bars = s.e.m 
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Chapter VI: Concluding Statements 
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The clinical benefits of HSCT are only hindered by the development of 
GVHD. With greater understanding of the underlying mechanisms involved in the 
development of chronic GVHD new therapies can be brought into the clinic. The 
data presented here are the first to demonstrate the underlying mechanisms and 
pathogenesis in a clinically relevant murine model. We demonstrated the 
necessity of B cells to develop from bone marrow derived cells to drive chronic 
GVHD pathogenesis. We also showed that there was an increase in GC activity 
and that by eliminating follicular dendritic cells by blocking LTβR signaling we 
could therapeutically decrease chronic GVHD pathology. However, depleting B 
cells after the onset of disease was not sufficient for preventing disease 
progression. The therapeutic depletion of B cells has had controversial results, 
but prophylactic depletion of B cells could be beneficial for disease treatment. 
Building off of these findings, we investigated the role T cells play in the GC 
reaction. We demonstrated that the increase in GC size and frequency correlated 
with an increase in Tfh cells. These cells demonstrated to be required for the 
progression of disease. IL21 is a key cytokine produced by donor T cells for 
development of chronic GVHD. These cells required the chemokine receptor 
CXCR5 for migration of T cells to the B cell follicle for iniation of disease. The 
discovery that GCs are important for the development of chronic GVHD has 
many implications on the development of new therapies. Furthermore, blocking 
BCR signaling is important for the disruption of disease. Using inhibitors for Syk 
and Btk have demonstrated to be successful in preventing disease progression. 
By treating mice with inhibitors to key B cell survival and proliferation molecules 
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the development of chronic GVHD is prevented by targeting hyperactive B cells. 
This demonstrates the importance of preventing B cell activation and not just 
depletion of the cells. These data are confirmed when we target the Tec-family 
kinases, BTK and ITK during chronic GVHD. We verified hyperactivity in BTK 
phosphorylation in B cells during chronic GVHD and revealed that inhibition with 
Ibrutinib was sufficient for prevention of disease. This was due to BTK expression 
in B cells and possibly ITK expression in T cells. 
These data presented from the chronic GVHD murine model with 
associated BOS are key in linking experimental data to clinical applications. All of 
the proposed therapeutic approaches have effects on the progression of disease 
and potentially reverses some of the features of chronic GVHD. It will be 
necessary to determine the effects the proposed therapeutics have on infections 
and future malignancies due to immunosuppression. Experiments challenging 
mice with virus and bacteria will be necessary for determining the effects on 
other aspects of the immune system. However, in many of the therapies 
proposed we are potentially restoring homeostatic levels of stimulation (anti-
ICOS, anti-CD40L, anti-IL21) or targeting hyperactive B cells (Fostamatinib and 
Ibrutinib); this could allow for a therapeutic effect with minimal 
immunosuppressive side effects. Finally, since chronic GVHD is a late-term 
disease it is unlikely that relapse of malignancies would occur, but the 
occurrence of new malignancies could be increased due to decreased immune 
surveillance. 
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 Here we have presented data mainly from one murine model, the BOS 
model of chronic GVHD, with supplemental data from a scleroderma model of 
chronic GVHD. The use of multiple models will be necessary to evaluate 
potential mechanisms of disease as well as evaluate novel therapies for multiple 
syndromes. We have demonstrated several overlapping pathologies of these 
models even though the disease manifestations might be divergent. For 
example, both models demonstrated an increase in BTK and ITK activity and 
treatment with Ibrutinib was able to ameliorate disease progression. Finally other 
models of chronic GVHD have demonstrated the importance of IL21 production 
and IL17 production consistent with the BOS model134.  
 Even though novel findings have been discovered, new questions have 
emerged. Plasma cells are antibody-producing cells that differentiate from GC B 
cells. The generation of plasma cells could be an explanation for the 
ineffectiveness of therapeutic B cell depletion due to their lack of expression of 
key B cell surface molecules. The role of plasma cells during chronic GVHD 
needs to be fully evaluated to determine if depletion therapies could have 
beneficial effects. The roles of regulatory cells in chronic GVHD have yet to be 
determined. It has been well documented that regulatory T (Treg) cells play a 
pivotal role in the prevention of acute GVHD135. T follicular regulatory cells are 
involved in controlling the GC response. T follicular regulatory cells might prevent 
the GC reaction and prevent the progression of chronic GVHD. The regulation of 
the GC response could prevent the production of high-affinity antibodies and the 
progression of B cells to differentiated plasma cells. Novel therapies could be 
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applied by understanding the induction of T follicular regulatory. The PD-1 
pathway is necessary for maintenance of T follicular regulatory cells136. 
Unpublished data demonstrates that blocking PD-1 with a mAb during active 
chronic GVHD increases T follicular regulatory cell numbers in the GC and 
prevents the development of BOS. However, recent findings in a scleroderma 
model of chronic GVHD found that PD-1 blockade increases severity of chronic 
GVHD137. It will be important to compare the progression of disease between 
multiple models to determine the full mechanism of PD-1 during chronic GVHD. 
Finally, data presented here have paved the way for novel therapeutic 
studies using direct or epigenetic inhibition of the GC response. The master 
transcriptional regulator Bcl6 is necessary for GC B cells as well as Tfh cells. By 
direct inhibition of the Bcl6 regulator by petidomimetics138 we can prevent the 
development of chronic GVHD by blocking the germinal center reaction 
(unpublished data). Furthermore, epigenetic regulation of the GC is another 
potential target for amelioration of chronic GVHD. The EZH2 protein complex is 
upregulated in GC B cells and alloreactive T cells139, 140. Targeting EZH2 
expression has a therapeutic effect in Diffuse Large B cell Lymphoma. New 
pharmaceutical inhibitors of the EZH2 complex are being generated and have 
demonstrated to have positive effects on the progression of chronic GVHD 
(Unpublished Data). These new findings are consistent with the presented data 
that GCs and Tfh are necessary for the progression of chronic GVHD. 
 Support from other CD4 helper T cells is necessary for chronic 
GVHD as well, however, less is known. For example the role of Th17 cells and 
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the production of IL17 has been demonstrated to be important. Th17 cells are 
have demonstrated to be involved in the initiation of the germinal center 
response and have demonstrated to increase the B cell activation following 
immunization141. In addition, Th17 cells are important for the initiation of ectopic 
lymphoid follicles in autoimmune diseases142. While Th17 cells have been 
demonstrated to increase chronic GVHD105, 143, 144, their exact role in 
development of disease remains undefined. Pathways for TH17 differentiation 
have been implicated in disease progression in models of scleraderma chronic 
GVHD. The induction of STAT3, a necessary transcription factor for Th17 
differentiation, is necessary for the manifestation of scleroderma lesions107.  
Unpublished observations have demonstrated the importance of STAT3 
induction in both bone marrow derived B cells and donor mature T cells. Finally, 
G-CSF administration promotes the induction of Th17 cells and has been linked 
to increased pathology in the scleroderma model of cGVHD143, 145. Together 
these data indicate a role for Th17 cells during both scleroderma and BOS 
chronic GVHD. Therapeutic interventions that block IL17 production could be 
beneficial. A novel regulator of Th17 cells is the Endothelial Protein C Receptor 
(EPCR), which binds Activated Protein C. After binding the ligand, EPCR is 
endocytosed and provides anti-inflammatory and barrier cytoprotective effects. 
We have seen a decrease in pathogenic pulmonary function when mice with 
chronic GVHD were treated with Activated Protein C (unpublished observations), 
indicating that the EPCR pathway might be a novel regulator of Th17 cells during 
chronic GVHD. In addition, inhibition of IL17 by pharmaceutical inhibitors has 
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demonstrated to have beneficial effects. The selective ROCK2 inhibitor KD025 
was demonstrated to decrease both IL21 and IL17 production from healthy donor 
peripheral blood cells146. We were able to reduce lung pathology in mice when 
we administered KD025 during chronic GVHD (Unpublished Data). The 
regulation or inhibition of pathogenic Th17 cells during chronic GVHD has great 
therapeutic potential. Since multiple models of both lung and skin pathology 
demonstrate a role of Th17 involvement, these data have strong implications for 
clinical translation. 
Presented have defined potential mechanisms in support of our 
hypothetical model of chronic GVHD (Chapter 1, Figure 1). We have defined the 
GC reaction as a mandatory process for the production of high-affinity 
pathogenic antibodies facilitated by Tfh. We have demonstrated the cell-signaling 
cascade necessary for B cell proliferation and maintenance. New understanding 
of disease progression and evaluation of novel therapeutics will be necessary for 
the successful treatment of chronic GVHD. The key findings presented lay the 
foundation of novel research to lead to potential therapies. 
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